Sialic acid (A-(2-6))-D-aminopyranose derivatives, synthesis methods and uses thereof

ABSTRACT

N-acyl modified sialic acid (α-(2→6))-D-aminopyranose derivatives, their synthesis methods and uses are disclosed. Sialic acid (α-(2→6))-D-aminopyranose derivatives represented by formula 1 are synthesized by using D-aminogalactose (glucose) and sialic acid as raw materials, which are coupled with carrier proteins or polypeptides to obtain glycoprotein (glycopeptide) conjugates. Acetyl is replaced by derivative acyl in the structures of said compounds, therefore the compounds show good activity in antitumor vaccines.

CROSS REFERENCE TO RELATED APPLICATIONS AND CLAIM OF PRIORITY

This patent application is a National Phase application under 35 U.S.C. §371 of International Application No. PCT/CN2011/000610, filed on Apr. 8, 2011, entitled SIALIC ACID (α-(2→6))-D-AMINOPYRANOSE DERIVATIVES, SYNTHESIS METHODS AND USES THEREOF, which claims priority to Chinese Patent Application number 201010202388.5, filed on Jun. 9, 2010, entire contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to the glycoconjugates, the sialic acid (α-(2→6))-D-aminopyranose derivatives, their conjugates to proteins or polypeptides and the synthesis methods thereof are of particular interest. And the present invention also relates to the application of these compounds in the preparation of anti-tumor drugs. The present invention falls within the area of anti-tumor vaccines.

2. Description of the Background Art

In recent years, vaccines based on the tumor-associated carbohydrate antigens (TACAs) are regarded as one of the research hotspots. STn antigen, a sialic acid-containing disaccharide, is expressed abundantly on breast, prostate, pancreas, colorectal, lung, gastric, and ovarian cancers; but only expressed limitedly on normal cells, which makes STn may serve as a important target in tumor immunotherapy. Based on this, Theratope® (acquired by Merck KGaA), a STn-KLH (keyhole limpet hemocyanin) conjugate, was developed at Biomira Inc., Canada to prevent metastasis of breast and rectal cancers. However, Theratope® was found not to improve time to progression (TTP) or overall survival (OS) when subjected to phase III clinical trial. Improved TTP was achieved only when patients were treated in conjugation with hormone therapy, leading to the prolonged time by 2.5 months (previously 5-8 months) of administration of hormone alone. The dependence on hormone of its anti-tumor activity eclipsed the efficacy of Theratope®. The major obstacle of carbohydrate-based anti-tumor vaccines, as was encountered by Theratope®, is their unsatisfactory performance in inducing immune responses. The conjugation of carbohydrate antigens to immunogenic carrier proteins was generally adopted, but was proved partially by Theratope® relatively ineffective for tumor-associated antigens.

SUMMARY

In one aspect, the present invention provides the solution in the first place to improve the poor immunogenicity of natural carbohydrate-based anti-tumor vaccines by designing and synthesizing novel modified tumor-associated carbohydrate antigens, a type of glycoproteins (-polypeptides) with improved efficacy for anti-tumor therapy.

In a further aspect, the present invention provides the process of preparing the above-mentioned glycoproteins (-polypeptides).

The present invention is to solve the technical problem is achieved by the following technical means:

-   Firstly, the present invention supplies the sialic acid     (α-(2→6))-D-aminopyranose derivatives or salts of the following     general formula (1), wherein:

-   R₁ is optionally acylamino, —NH₂, —N₃ or —OH; the preferred     acylamino groups are —NHC(O)CH_(x)Cl_(y), —NHC(O)CH_(x)F_(y),     —NHC(O)CH_(x)Br_(y), —NHC(O)H, —NHC(O)C_(a)H_(2a+1),     —NHC(O)C_(a)H_(2a)OH, —NHC(O)C_(b)H_(2b−1), —NHC(O)C_(b)H_(2b−3),     where x or y is 0, 1, 2 or 3, and the sum of x and y is 3; a is an     integer between 1 and 20; b is an integer between 2 and 20; -   R₂ is optionally acylamno, —NH₂, —N₃ or —OH; the preferred amido     groups are —NHC(O)CH_(p)Cl_(q), —NHC(O)CH_(p)F_(q),     —NHC(O)CH_(p)Br_(q), —NHC(O)H, —NHC(O)C_(a)H_(2a+1),     —NHC(O)C_(a)H_(2a)OH, —NHC(O)C_(b)H_(2b−1), —NHC(O)C_(b)H_(2b−3),     where p or q is 0, 1, 2 or 3, and the sum of p and q is 3; a is an     integer between 1 and 20; b is an integer between 2 and 20; -   R₃ is optionally —CO₂H, —CH₂OH, —CO₂M, C(O)NHOH or hydrogen, where M     is optionally alkyl, aryl or heteroaryl; the orientation of the R₃     is equatorial bond or axial bond; -   R₄ is optionally substituent group containing alkenyl, alkynyl,     azido, aldehyde, protected acetal, maleimido, mercapto group,     protected mercapto group, seleno, protected seleno, —NH2 or —ONH2,     groups, preferably, R4 is allyl group; -   R5 is —OH; the orientation of the R5 is equatorial bond or axial     bond; -   R6 is optionally hydrogen or β-galactosyl-. -   The compounds in Formula 1 are conjugated to proteins or     polypeptides to give the corresponding glycoconjugates. -   It is understood that compounds in the present invention may be     further prepared as salts, which are included in this invention as     well.

The salts are preferentially pharmaceutically acceptable and are prepared with non-toxic bases such as sodium bicarbonate, potassium bicarbonate or ammonia, etc. Apart from the preferred ones, other salts are also included in this invention.

The glycoproteins (or -polypeptides) are further prepared as anti-tumor vaccine. Compared with Theratope®, the vaccination results on mice showed 3 to 20-fold increase in antibody titers and improved IgG/IgM ratios by 2 to 14 folds.

The another question the present invention wants to solve is to provides the process of preparing the compound of the following general formula (1).

-   The another question is to be solved by the following technical     means: -   A process of preparing N-acyl modified sialic acid     (α-(2→6))-D-aminopyranose derivatives or salts of claim 1, which     concluding following steps: -   Using the sialic acid with 5-naked amino- and/or aminogalactose     (aminoglucose) with 2-naked amino- as raw materials, the process is     promoted by acylation reaction in the solvents with carboxylic acid     anhydrides, carboxylic acids or carboxylic esters in the presence of     the reaction promoter. -   The preferential raw materials may be allyl     4-O-(5-amino-3,5-dideoxy-α-neuraminopyranosyl)-2-acetylamino-2-deoxy-α-D-galactopyranoside,     allyl     4-O-(5-acetylamino-3,5-dideoxy-α-neuraminopyranosyl)-2-amino-2-deoxy-α-D-galactopyranoside     or allyl     4-O-(5-amino-3,5-dideoxy-α-neuraminopyranosyl)-2-amino-2-deoxy-α-D-galactopyranoside.

The aliphatic carboxylic anhydride may be chosen, with/without fluoro or chloro substituents. Acetic anhydride, propionic anhydride, n-butyric anhydride, iso-butyric anhydride and caproic anhydride are preferred;

The aliphatic carboxylic acid may be chosen, with/without fluoro or chloro substituents in the aliphatic chain. Mono-, di- or trifluoroaccetic acids and mono- or dichloroacetic acids are preferred;

The aliphatic carboxylic ester may be chosen, with/without fluoro or chloro substituents. Methyl mono-, di- or trifluoroaccetates and methyl dichloroacetates are preferred;

The promoter may be organic or inorganic base;

The solvent may be water or organic solvents.

-   Still further described below is the technical solution of preparing     the glycoconjugate:

(1) The disaccharide in Formula 1 undergoes ozonization to give the corresponding aldehyde; (2) The aldehyde undergoes reductive amination with the carrier protein (or polypeptide) to give the conjugate.

-   Starting from D-galactosamine (D-glucosamine) and sialic acid, the     present invention furnishes the disaccharide derivatives shown in     Formula 1 and the corresponding glycoconjugates. In present     invention, the acetyl group in natural mono saccharide unit, e.g.     sialic acid or amino sugar, is replaced by various modified acyl     substituents with novel structures, Some of the synthesized     glycoconjugates exhibit improved activities as anti-tumor vaccines.     The vaccination results on mice showed that some structurally     derivatized TACA-based vaccines possess enhanced immunogenicity with     increased antibody titers and raised IgG/IgM ratios. Since STn     antigen is expressed abundantly on breast, prostate, pancreas,     colorectal and ovarian cancers, the strategy based on antigen     modifications with fluoric or other suitable substitutions might     find applications in the development of carbohydrate-based and     peptide-based vaccines.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows formula of N-acyl modified sialic acid α-(2→6)-D-aminopyranose derivatives.

FIG. 2 shows formula of Compounds 1-42 and 61-64.

FIG. 3 shows formula of Compounds 43-60 and the synthetic routes of some depicted compounds; and the synthetic route of the antigen. Reagents and conditions: (a-b) see U.S. Pat. No. 6,013,779; (c) strongly acidic cation exchange resin, MeOH, reflux, 97%; (d) TMSOTf, −72° C., THF, for 48 (46+47): 84%, α/β=1/1.2; for 52 (46+51): 81%, α/β=2.6/1; for 54 (47+53): 58%, α only; (e) i. NaOMe/MeOH; ii. 1N NaOH; iii. 2N NaOH, 90° C.; (f) Acylation; (g) NaOMe/MeOH, then 2N NaOH, 86%; (h) i. NaOMe/MeOH, then 1N NaOH; ii. H₂S/pyridine/TEA, 67%; (i) for 37, NH₂OH, KCN, THF, 50%; (j) for 38, NaBH₄, MeOH, 94%.

FIG. 4 shows the synthetic routes of Compounds 60 and 53.

FIG. 5 shows the routes of N-acylation; (i) carboxylic anhydride, MeOH, NaHCO₃; or (2) carboxylic ester, TEA, MeOH; carboxylic acid, HBTU, DMF.

FIG. 6 shows the combination between the mice sera and the tumor cells 13th days after 3^(rd) vaccination of mice with the synthetic glycoconjugates.

DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION

Below is the detailed description of the embodiments revealing the advantages of the present invention. The scope of protection of the present invention is not constrained by the representative embodiments described herein. And it should be noted that modificative and alternative technical solutions are included in this invention as well.

Embodiment 1 Synthesis of Compound 2

Compound 48 (100 mg, 0.119 mmol) (For its synthesis, see Embodiment 42.) was dissolved in 10 ml methanol, NaOMe/MeOH (30%, 0.02 g, 0.11 mmol) was added. The mixture was stirred at R.T. for 0.5 h. The reaction mixture was neutralized with 1N HCl/MeOH to pH=3. The mixture was concentrated in vacuum. The residue was purified on a Biogel P-2 column with water as the eluent. Fractions containing the expected product were collected to afford 2 (yield=95%).

¹H-NMR (400 MHz, D₂O) δ 5.90-5.77 (m, 1H), 5.22 (dd, 1H, J₁=1.6 Hz, J₂=17.6 Hz), 5.14 (d, 1H, J=10.4 Hz), 4.75 (d, 1H, J=3.6 Hz, anomeric H of GalNAc), 4.15 (dd, 1H, J₁=4.0 Hz, J₂=13.6 Hz), 4.05 (dd, 1H, J₁=4.0 Hz, J₂=10.8 Hz), 3.96-3.87 (m, 3H), 3.82-3.74 (m, 5H), 3.60-3.48 (m, 4H), 3.46 (dd, 1H, J₁=1.6 Hz, J₂=8.8 Hz), 2.59 (dd, 1H, J₁=4.4 Hz, J₂=12.4 Hz, siaH-3 eq), 1.91 (s, 6H), 1.56 (t, 1H, J=12.4 Hz, siaH-3ax); ¹³C-NMR (75 MHz, D₂O) 175.59, 175.16, 173.99, 134.221, 118.64, 100.94, 96.79, 73.14, 72.33, 70.09, 69.28, 69.05, 68.80, 68.12, 64.32, 63.17, 52.42, 50.42, 40.83, 22.59, 22.47; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₆N₂NaO₁₄]⁺, 575.2059. found, 575.2050

Embodiment 2 Synthesis of Compound 3

10 mg Compound 14 [allyl 4-O-(5-amino-3,5-dideoxy-α-D-neuraminopyranosyl)-2-acetylamino-2-deoxy-α-D-galactopyranoside, (10 mg) See Embodiment 13] used as raw material was dissolved in 1 ml methanol. For its synthesis, 2-3 mg NaHCO3 was added. On ice bath, one drop of propionic anhydride (˜5 μL) was added. The reaction mixture was stirred for 1 h. Another drop of propionic anhydride was added. After TLC showed the reaction is largely completed. The reaction mixture was then stirred overnight. The temperature was raised to R.T. After TLC showed the reaction is completed, the reaction mixture was neutralized with strong acidic resin and filtered The filtrate was concentrated in vacuum. The residue was purified on a Biogel P-2 column with water as the eluent and was further purified by C18 reverse phase column chromatography with water-water/MeOH as eluent, affording 3 (8-9 mg, yield=75-85%).

¹H-NMR (500 MHz, D₂O) δ 6.02-5.96 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 16.5 Hz), 5.29-5.24 (m, 1H), 4.93 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.21 (ddt, 1H, J₁=J₂=1.5 Hz, J₃=5.5 Hz, J₄=13.0 Hz), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.08 (dd, 1H, J₁=5.0 Hz, J₂=8.0 Hz), 4.04-4.00 (m, 2H), 3.93-3.80 (m, 5H), 3.71-3.61 (m, 4H), 3.56 (dd, 1H, J₁=1.5, J₂=9.0 Hz), 2.73 (dd, 1H, J₁=5.0 Hz, J₂=12.5 Hz, siaH-3 eq), 2.28 (q, 2H, J=12.5 Hz), 1.69 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax), 1.12 (t, 3H, J=8.0 Hz); ¹³C-NMR(75 MHz, D₂O) δ179.58, 175.13, 173.98, 134.19, 118.63, 100.91, 96.76, 73.15, 72.31, 70.08, 69.26, 69.03, 68.80, 68.68, 68.09, 64.29, 63.13, 52.27, 50.40, 40.88, 29.80, 22.46, 10.08; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₃H₃₈N₂NaO₁₄]⁺, 589.2215. found, 589.2223

Embodiment 3 Synthesis of Compound 4

This compound was prepared from Compound 14 and n-butyric anhydride, affording 4 (yield=75-85%). The synthetic procedure was the same as that of Compound 3.

¹HNMR (500 MHz, D₂O) δ 6.02-5.96 (m, 1H), 5.35 (ddd, 1H, J₁=1.5 Hz, J₂=3.0 Hz, J₃=17.0 Hz), 5.26 (dd, 1H, J₁=1.0 Hz, J₂=3.0 Hz, J₃=10.5 Hz), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.22 (ddt, 1H, J₁=J₂=1.5 Hz, J₃=5.5 Hz, J₄=13.0 Hz), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.06 (dd, 1H, J₁=4.0 Hz, J₂=8.0 Hz), 4.04-4.00 (m, 2H), 3.93-3.80 (m, 5H), 3.71-3.61 (m, 4H), 3.56 (dd, 1H, J₁=1.5, J₂=9.0 Hz), 2.73 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.26 (t, 2H, J=7.5 Hz), 2.03 (s, 3H), 1.68 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax), 1.60 (hexad, 2H, J=7.5 Hz), 0.91 (t, 3H, J=7.5 Hz); ¹³C-NMR(75 MHz, D₂O) δ 178.88, 175.31, 174.08, 134.40, 118.81, 101.08, 96.98, 73.36, 72.47, 70.26, 69.45, 69.22, 69.10, 68.80, 68.29, 64.46, 63.35, 52.50, 50.59, 41.10, 38.59, 22.66, 19.74, 13.56; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₄H₄₀N₂NaO₁₄]⁺, 603.2372. found, 603.2379

Embodiment 4 Synthesis of Compound 5

This compound was prepared from Compound 14 and iso-butyric anhydride, affording 5 (yield=75-85%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 5.95-6.02 (m, 1H), 5.36 (ddd, 1H, J₁=1.5 Hz, J₂=3.0 Hz, J₃=17.5 Hz), 5.26 (m, 1H), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.22 (ddt, 1H, J₁=J₂=1.5 Hz, J₃=5.5 Hz, J₄=13.0 Hz), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.06 (dd, 1H, J_(1=4.0) Hz, J₂=8.0 Hz), 4.04-3.98 (m, 2H), 3.94-3.78 (m, 5H), 3.74-3.60 (m, 4H), 3.52 (dd, 1H, J₁=1.5 Hz, J₂=9.0 Hz), 2.75 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.54 (heptad, 1H, J=7.0 Hz), 2.02 (s, 3H), 1.68 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax), 1.12 (d, 3H, J=7.0 Hz), 1.11 (d, 3H, J=7.0 Hz); ¹³C-NMR(125 MHz, D₂O) δ 182.92, 174.64, 134.01, 119.50, 103.39, 101.79, 100.52, 78.99, 76.22, 75.91, 75.50, 75.14, 73.66, 73.54, 72.50, 71.40, 70.10, 68.95, 68.81, 68.19, 63.26, 61.76, 60.80, 52.19, 40.55, 35.95, 19.69, 19.16; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₄H₄₀N₂NaO₁₄]⁺, 603.2372. found, 603.2379

Embodiment 5 Synthesis of Compound 6

This compound was prepared from Compound 14 and caproic anhydride, affording 6 (yield=100%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.02-5.96 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₁=3.0 Hz, J₂=17.5 Hz), 5.26 (dd, 1H, J₁=1.5 Hz, J₃=10.5 Hz), 4.92 (d, 1H, J=4.0 Hz, anomeric H of GalNAc), 4.22 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.08-4.00 (m, 3H), 3.93-3.80 (m, 5H), 3.71-3.61 (m, 4H), 3.56 (dd, 1H, J₁=1.5, J₂=9.0 Hz), 2.73 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.28 (t, 2H, J=7.5 Hz), 2.03 (s, 3H), 1.68 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax), 1.60 (m, 2H), 1.29 (m, 4H), 0.86 (t, 3H, J=7.0 Hz); ¹³C-NMR(75 MHz, D₂O) δ 179.14, 175.31, 174.12, 134.40, 118.82, 101.11, 96.98, 73.38, 72.51, 70.27, 69.45, 69.22, 69.16, 68.79, 68.29, 64.46, 63.41, 52.49, 50.59, 41.14, 36.62, 31.25, 25.82, 22.66, 22.39, 13.95; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₆H₄₄N₂NaO₁₄]⁺, 631.2685. found, 631.2684

Embodiment 6 Synthesis of Compound 7

10 mg Compound 14 used as raw material was dissolved in 1 ml methanol, under N₂ atmosphere, triethylamine (TEA) (0.4 mL) was added. On ice bath, methyl fluoroacetate (0.2 mL) was added. The temperature was raised to R.T. The reaction mixture can be heated when necessary. When the reaction was near completion (by TLC monitoring), the mixture was concentrated in vacuum. The residue was purified by C18 reverse-phase column chromatography with MeOH/water as eluent and then on a Biogel P-2 column with water as the eluent. The product was still further purified by C18 reverse-phase column chromatography with water-water/MeOH as eluent, affording 7 (yield=75-85%).

¹H-NMR (500 MHz, D₂O) δ 6.01-5.92 (m, 1H), 5.38-5.30 (m, 1H), 5.28-5.22 (m, 1H), 4.92 (d, 1H, J=4.0 Hz, anomeric H of GalNAc), 4.92 (d, 2H, J=46.0 Hz), 4.23-4.17 (m, 1H), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.06 (dd, 1H, J₁=4.0 Hz, J₂=8.0 Hz), 4.04-3.80 (m, 9H), 3.71 (dd, 1H, J₁=3.5 Hz, J₂=10.0 Hz), 3.64 (dd, 1H, J₁=6.0 Hz, J₂=12.5 Hz), 3.59-3.55 (m, 1H), 2.72 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (s, 3H), 1.79 (t, 1H, J=12.5 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.34, 172.48, 172 (d, 1C, J=18.25 Hz), 134.37, 118.80, 100.02, 97.02, 80 (d, 1C, J=180.25 Hz), 73.15, 71.89, 70.20, 69.50, 69.26, 68.94, 68.29, 68.15, 64.56, 63.60, 52.10, 50.56, 40.20, 22.64; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₅FN₂NaO₁₄]⁺, 593.1965. found, 593.1977

Embodiment 7 Synthesis of Compound 8

This compound was prepared from Compound 14 and methyl difluoroacetate, affording 8 (yield=69%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.17 (t, J=54.0 Hz), 6.02-5.92 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₁=3.0 Hz, J₂=17.5 Hz), 5.26 (dd, 1H, J₁=1.5 Hz, J₃=10.5 Hz), 4.92 (d, 1H, J=3.5, anomeric H of GalNAc), 4.22 (dd, 1H, J₁=5.5 Hz, J₂=13.0 Hz), 4.14 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.08-3.89 (m, 9H), 3.75 (ddd, 1H, J₁=4.5 Hz, J₂=9.5 Hz, J₃=12.0 Hz), 3.65-3.61 (m, 2H), 3.56 (dd, 1H, J₁=1.5, J₂=9.0 Hz), 2.74 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (s, 3H), 1.71 (t, 1H, J=12.5 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.32, 174.05, 166.30 (m, 1C, CF₂HCO—), 134.41, 118.81, 109.03 (t, 1C, J=247.0 Hz, CF₂HCO—), 101.13, 96.98, 72.70, 72.60, 70.28, 69.46, 69.24, 68.86, 68.73, 68.28, 64.55, 63.33, 52.62, 50.59, 40.95, 22.65; HRMS (m/z): [M+H]⁺ calcd. for [C₂₂H₃₅F₂N₂O₁₄]⁺, 589.2051. found, 589.2053

Embodiment 8 Synthesis of Compound 9

This compound was prepared from Compound 14 and methyl trifluoroacetate, affording 9 (yield=85%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.02-5.91 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.26 (dd, 1H, J₁=1.5 Hz, J₃=10.5 Hz) 4.93 (d, 1H, J=4.0 Hz, anomeric H of GalNAc), 4.20 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.07 (dd, 1H, J₁=4.0 Hz, J₂=11.0 Hz), 4.04-3.80 (m, 9H), 3.70 (dd, 1H, J₁=4.0 Hz, J₂=10.0 Hz), 3.66-3.60 (m, 1H) 3.53 (dd, 1H, J₁=1 Hz, J₂=9.0 Hz), 2.73 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (m, 3H), 1.79 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.34, 172.69, 160.19 (q, J=37.2 Hz), 134.39, 118.80, 116.49 (q, J=284.5 Hz), 100.23, 97.02, 72.72, 72.01, 70.21, 69.50, 69.26, 69.00, 64.61, 63.54, 53.07, 50.57, 49.60, 40.36, 22.65; HRMS (m/z): [M+H]⁺ calcd. for [C₂₂H₃₄F₃N₂O₁₄]⁺, 607.1957. found, 607.1936

Embodiment 9 Synthesis of Compound 10

Under N₂ atmosphere, Compound 14 (10-15 mg, 0.02-0.03 mmol), HBTU [O-(benzotriazol-1-yl)-tetramethyluronium hexafluorophosphate] (1.3 eq. per amino group) and fluoroacetic acid were dissolved in 2 ml DMF at R.T., DIPEA (N,N-diisopropylethylamine) (13 eq. to Compound 14) was added. After 1-4 h, the reaction was near completion (by TLC monitoring). The mixture was concentrated in vacuum. The residue was purified by C18 reverse-phase column chromatography with MeOH/water as eluent and then on a on a Biogel P-2 column with water as the eluent. The product was still further purified by C18 reverse-phase column chromatography with water-water/MeOH as eluent, affording 10 (yield=56%).

¹H-NMR (300 MHz, D₂O) δ 5.84-5.65 (m, 1H), 5.35 (d, 1H, J=17.5 Hz), 5.26 (d, 1H, J=10.5 Hz), 4.72 (d, 1H, J=3.6 Hz, anomeric H of GalNAc), 4.04-3.59 (m, 15H), 3.49-3.35 (m, 3H), 2.52 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 1.83 (m, 3H), 1.56 (t, 1H, J₁=J₂=12.0 Hz, siaH-3ax); ¹³C-NMR(75 MHz, D₂O) δ 175.13, 172.86, 170.99, 134.13, 118.60, 100.08, 96.78, 72.91, 71.86, 70.01, 69.28, 69.04, 68.75, 68.07, 64.37, 63.32, 52.72, 50.35, 42.82, 40.26, 22.42; HRMS (m/z): [M+Na]⁺ calcd. for C₂₂H₃₅ClN₂NaO₁₄, 609.1669. found, 609.1675

Embodiment 10 Synthesis of Compound 11

This compound was prepared from Compound 14 and methyl dichloroacetate, affording 11 (yield=46%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (300 MHz, D₂O) δ 6.14 (s, 1H), 5.87-5.72 (m, 1H), 5.17 (d, 1H, J=17.1 Hz), 5.08 (d, 1H, J=10.2 Hz), 4.77 (d, 1H, J=3.6 Hz, anomeric H of GalNAc), 4.06-3.56 (m, 18H), 2.56 (dd, 1H, J₁=4.0 Hz, J₂=12.6 Hz, siaH-3 eq), 1.86 (s, 3H), 1.62 (t, 1H, J₁=J₂=12.0 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.34, 172.45, 168.22, 134.39, 118.81, 100.03, 97.03, 73.09, 71.95, 70.20, 69.51, 69.27, 69.15, 68.30, 68.00, 66.93, 64.58, 63.61, 53.25, 50.56, 40.32, 22.65; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₄Cl₂N₂NaO₁₄]⁺, 643.1279. found, 643.1304

Embodiment 11 Synthesis of Compound 12

This compound was prepared from Compound 14 and methyl trichloroacetate, affording 12 (yield=64%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.02-5.92 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₂=17.0 Hz), 5.26 (d, 1H, J=10.5 Hz), 4.93 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.21 (dd, 1H, J₁=5.5 Hz, J₂=12.5 Hz), 4.15 (dd, 1H, J₁=4.0 Hz, J₂=12.5 Hz), 4.09-3.83 (m, 9H), 3.67-3.57 (m, 3H) 3.53 (dd, 1H, J₁=1 Hz, J₂=9.0 Hz), 2.75 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (s, 3H), 1.74 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.34, 173.76, 165.54, 134.42, 118.82, 100.90, 97.00, 72.67, 72.59, 70.28, 69.48, 69.25, 69.22, 68.29, 64.58, 63.38, 54.58, 50.59, 41.13, 22.67; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₃Cl₃N₂NaO₁₄]⁺, 677.0890. found, 677.0902

Embodiment 12 Synthesis of Compound 13

Compound 14 (15.0 mg, 0.029 mmol) was dissolved in 2.0 ml methanol, CuSO₄ (0.5 mg, 0.003 mmol) was added. TfN₃/pyridine (8.0 mL, 0.56 mmol See Tetrahedron Lett. 2005, 46, 8993-8995) was then added to the mixture. The reaction went to completion after 1 h (by TLC monitoring). The mixture was concentrated in vacuum. The residue was purified by C18 reverse-phase column chromatography with MeOH/water as eluent and then on a Biogel P-2 column with water as the eluent. The product was still further purified by C18 reverse-phase column chromatography with water-water/MeOH as eluent, affording 13 (yield=96%).

¹H-NMR (500 MHz, D₂O) δ 5.93-6.00 (m, 1H), 5.35 (ddd, 1H, J₁=1.5 Hz, J₂=3.0 Hz, J₃=17.5 Hz), 5.26 (ddd, 1H, J₁=1.0 Hz, J₂=2.5 Hz, J₃=10.5 Hz), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.21 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.14 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.08-3.99 (m, 3H), 3.93-3.88 (m, 4H), 3.80 (dd, 1H, J₁=2.0 Hz, J₂=9.0 Hz), 3.72-3.64 (m, 2H), 3.64-3.58 (m, 2H), 3.47 (dd, 1H, J₁=J₂=10.0 Hz), 2.72 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, siaH-3 eq), 2.03 (s, 3H), 1.68 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.33, 173.99, 134.42, 118.80, 101.11, 96.98, 73.27, 72.67, 70.28, 70.13, 69.46, 69.29, 69.25, 68.28, 64.58, 63.49, 63.33, 50.60, 40.80, 22.66; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₀H₃₂N₄NaO₁₃]⁺, 559.1858. found, 559.1847

Embodiment 13 Synthesis of Compound 14

Compound 52 (For its synthesis, see Embodiment 44) (380 mg, 0.426 mmol) was dissolved in 20 ml methanol, NaOMe/MeOH (30%, 0.02 g, 011 mmol) was added. The mixture was stirred at R.T. for 1 h. The mixture was concentrated in vacuum. The solution of NaOH in water (2N, 10 mL) was added. The mixture was stirred at R.T. for 10 h. The reaction mixture was neutralized with 1N HCl/MeOH to pH=3. The mixture was concentrated in vacuum. The residue was purified on a Biogel P-2 column with water as the eluent. Fractions containing the expected product were collected to afford 2 (yield=86%). The crude product may also be directly used in the next step.

¹H-NMR (500 MHz, D₂O) δ 5.97 (m, 1H), 5.35 (ddd, 1H, J₁=1.5 Hz, J₂=3.0 Hz, J₃=17.5 Hz), 5.26 (ddd, 1H, J₁=1.5 Hz, J₂=3.0 Hz, J₃=10.5 Hz), 4.93 (d, 1H, J=4.0 Hz, anomeric H of GalNAc), 4.20 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.14 (dd, 1H, J₁=3.5 Hz, J₂=12.0 Hz), 4.07 (dd, 1H, J₁=4.0 Hz, J₂=11.0 Hz), 4.04-3.89 (m, 7H), 3.80-3.71 (m, 3H), 3.62 (dd, 1H, J₁=4.0 Hz, J₂=10.5 Hz), 3.22 (t, 1H, J₁=J₂=10.0 Hz), 2.77 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (m, 3H), 1.71 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR (75 MHz, D₂O) δ 175.06, 173.57, 134.14, 118.57, 100.80, 96.71, 72.25, 72.15, 70.04, 69.20, 69.04, 68.37, 67.98, 67.72, 64.51, 62.77, 52.79, 50.34, 40.82, 22.45; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₀H₃₄N₂NaO₁₃]⁺, 533.1953. found, 533.1953

Embodiment 14 Synthesis of Compound 15

This compound was prepared from Compound 14 and bromoacetic acid, affording 15 (yield=37%). The synthetic procedure was the same as that of Compound 10.

¹H-NMR (500 MHz, D₂O) δ 6.02-5.92 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.26 (dq, 1H, J=1.5 Hz, 10.5 Hz), 4.92 (d, 1H, J=4.0 Hz, anomeric H of GalNAc), 4.22 (ddt, 1H, J₁=J₂=1.5 Hz, J₃=4.0 Hz, J₃=13.0 Hz), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=6.0 Hz), 4.07 (dd, 1H, J₁=4.5 Hz, J₂=8.0 Hz), 4.05-4.00 (m, 2H), 3.96-3.85 (m, 7H), 3.80 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 3.71 (ddd, 1H, J₁=4.5 Hz, J₂=9.5 Hz, J₃=12.0 Hz), 3.66-3.59 (m, 3H), 2.73 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.04 (s, 3H), 1.69 (dd, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.34, 174.12, 171.51, 134.42, 118.82, 101.15, 96.99, 73.13, 72.63, 70.29, 69.47, 69.24, 69.02, 68.30, 64.52, 63.38, 53.03, 50.61, 41.04, 28.73, 22.67; HRMS (m/z): [M+H]⁺ calcd. for [C₂₂H₃₆BrN₂O₁₄]⁺, 631.1344. found, 631.1324

Embodiment 15 Synthesis of Compound 16

This compound was prepared from Compound 26 [allyl 4-O-(5-acetylamino-3,5-dideoxy-α-D-neuraminopyranosyl)-2-amino-2-deoxy-α-D-galactopyranoside. See Embodiment 25] and propionic anhydride, affording 16 (yield=56%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.01-5.91 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₂=17.5 Hz), 5.25 (d, 1H, J=10.5 Hz), 4.92 (d, J=3.5 Hz, anomeric H of GalN), 4.21 (dd, 1H, J₁=5.0 Hz, J₂=12.5 Hz), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=11.5 Hz), 4.07 (dd, 1H, J₁=4.5 Hz, J₂=7.5 Hz), 4.04-3.99 (m, 2H), 3.94-3.81 (m, 5H), 3.73-3.62 (m, 4H), 3.57 (1H, J₁=1.5 Hz, J₂=9.0 Hz), 2.72 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (t, 1H, J₁=J₂=8.0 Hz), 2.29 (q, 2H, J=7.5 Hz), 2.03 (s, 3H), 1.70 (t, 1H, J₁=J₂=12.0 Hz, siaH-3ax), 1.11 (t, 3H, J₁=J₂=7.5 Hz); ¹³C-NMR (125 MHz, D₂O) δ 179.33, 175.76, 174.14, 134.36, 118.89, 101.13, 96.96, 73.33, 72.50, 70.28, 69.48, 69.25, 68.98, 68.22, 64.49, 63.36, 52.59, 50.49, 41.00, 29.84, 22.76, 10.29; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₃H₃₈N₂NaO₁₄]⁺, 589.2215. found, 589.2225

Embodiment 16 Synthesis of Compound 17

This compound was prepared from Compound 26 and n-butyric anhydride, affording 17 (yield=53%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.00-5.90 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₂=17.5 Hz), 5.26 (d, 1H, J₁=1.0 Hz, J₂=10.5 Hz), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.20 (dd, 1H, J₁=5.5 Hz, J₂=13.0 Hz), 4.14 (dd, 1H, J₁=3.5 Hz, J₂=11.5 Hz), 4.06 (dd, 1H, J₁=4.5 Hz, J₂=7.5 Hz), 4.03-3.99 (m, 2H), 3.94-3.80 (m, 5H), 3.71-3.61 (m, 4H), 3.78 (dd, 1H, J₁=1.5 Hz, J₂=9.0 Hz), 2.73 (dd, 1H, J₁=5.0, J₂=12.5 Hz, siaH-3 eq), 2.28 (t, 2H, J=7.0 Hz), 2.03 (s, 1H), 1.68 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax), 1.65-1.56 (m, 2H), 0.93 (t, 3H, J=7.5 Hz); ¹³C-NMR(125 MHz, D₂O) δ 178.26, 175.59, 173.89, 134.14, 118.82, 100.88, 96.8473.16, 72.29, 70.10, 69.36, 69.10, 68.78, 67.96, 64.33, 63.19, 52.41, 50.36, 40.79, 38.19, 22.59, 19.60, 13.26; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₄H₄₀N₂NaO₁₄]⁺, 603.2372. found, 603.2374

Embodiment 17 Synthesis of Compound 18

This compound was prepared from Compound 26 and iso-butyric anhydride, affording 18 (yield=76%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.00-5.90 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₂=17.0 Hz), 5.26 (d, 1H, J₁=10.0 Hz), 4.92 (d, 1H, J=4.0 Hz, anomeric H of GalN), 4.20 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz), 4.14 (dd, 1H, J₁=4.0 Hz, J₂=11.5 Hz), 4.06 (dd, 1H, J₁=4.5 Hz, J₂=8.0 Hz), 4.03-3.99 (m, 2H), 3.94-3.80 (m, 5H), 3.71-3.61 (m, 4H), 3.78 (dd, 1H, J₁=1.5 Hz, J₂=8.5 Hz), 2.73 (dd, 1H, J₁=4.5, J₂=12.5 Hz, siaH-3 eq), 2.56 (septenary, 1H, J=7.0 Hz), 2.03 (s, 3H), 1.83 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax), 1.10 (d, 3H, J=7.0 Hz), 1.09 (d, 3H, J=7.0 Hz); ¹³C-NMR(125 MHz, D₂O) δ 182.45, 175.76, 174.12, 134.31, 119.00, 101.11, 96.91, 73.32, 72.49, 70.29, 69.50, 69.28, 68.97, 6810, 64.49, 63.36, 52.58, 50.43, 40.98, 35.71, 22.76, 19.61, 19.19; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₄H₄₀N₂NaO₁₄]⁺, 603.2372. found, 603.2384

Embodiment 18 Synthesis of Compound 19

This compound was prepared from Compound 26 and caproic anhydride, affording 19 (yield=87%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.01-5.93 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₂=17.5 Hz), 5.26 (dd, 1H, J₁=1.0 Hz, J₂=10.5 Hz), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.22 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz), 4.15 (dd, 1H, J₁=4.0 Hz, J₂=11.0 Hz), 4.07 (dd, 1H, J₁=4.0 Hz, J₂=8.0 Hz), 4.08-4.00 (m, 2H), 3.93-3.80 (m, 5H), 3.71-3.61 (m, 4H), 3.56 (dd, 1H, J₁=1.5, J₂=9.0 Hz), 2.73 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.28 (m, 2H), 2.03 (s, 3H), 1.68 (t, 1H, J=12.5 Hz, siaH-3ax), 1.60 (m, 2H), 1.29 (m, 4H), 0.86 (t, 3H, J=7.0 Hz); ¹³C-NMR(125 MHz, D₂O) δ 178.62, 175.76, 174.12, 134.32, 118.98, 101.13, 97.02, 73.33, 72.50, 70.28, 69.54, 69.26, 68.98, 68.13, 64.48, 63.36, 52.59, 50.52, 40.99, 36.44, 31.14, 25.83, 22.76, 22.41, 13.95; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₆H₄₄N₂NaO₁₄]⁺, 631.2685. found, 631.2678

Embodiment 19 Synthesis of Compound 20

This compound was prepared from Compound 26 and methyl fluoroacetate, affording 20 (yield=77%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.02-5.92 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₂=17.0 Hz), 5.26 (d, 1H, J=10.5 Hz), 4.97 (d, J=4.0 Hz, anomeric H of GalN), 4.97&4.88 (d, 2H, J_(F,H)=46.5 Hz), 4.26 (dd, 1H, J₁=4.0 Hz, J₂=11.0 Hz), 4.22 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz), 4.08 (dd, 1H, J₁=4.5 Hz, J₂=8.0 Hz), 4.05-3.99 (m, 3H), 3.94-3.81 (m, 4H), 3.71-3.62 (m, 4H), 3.58 (dd, 1H, J₁=1.5 Hz, J₂=9.0 Hz), 2.72 (dd, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (s, 3H), 1.68 (t, 1H J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.77, 174.14, 171.89, 171.74, 134.35, 118.94, 101.13, 96.88, 81.18, 79.74, 73.33, 72.50, 70.33, 69.50, 69.22, 69.00, 68.10, 64.45, 63.36, 52.59, 50.28, 41.00, 22.76; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₅FN₂NaO₁₄]⁺, 593.1965. found, 593.1975

Embodiment 20 Synthesis of Compound 21

This compound was prepared from Compound 26 and methyl difluoroacetate, affording 21 (yield=78%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.19 (t, 1H, J_(F,H)=53.6 Hz), 6.01-5.91 (m, 1H), 5.34 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.25 (dq, 1H, J=1.5 Hz, 10.5 Hz), 4.99 (d, J=4.0 Hz, anomeric H of GalN), 4.26-4.19 (m, 2H), 4.10 (dd, 1H, J₁=4.0 Hz, J₂=8.0 Hz), 4.06-3.99 (m, 3H), 3.99-3.93 (m, 1H), 3.90-3.84 (m, 3H), 3.80-3.69 (m, 3H), 3.65 (dd, 1H, J₁=6.5 Hz, J₂=12.5 Hz), 3.57 (dd, 1H, J₁=1.5 Hz, J₂=8.5 Hz), 2.71 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, siaH-3 eq), 2.03 (s, 3H), 1.76 (t, J₁=J₂=12.0 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.73, 172.88, 166.05 (t, 1C), 134.29, 118.97, 118.79, 108.88 (t, 1C, J_(F-C)=246.1 Hz), 100.27, 96.61, 73.50, 71.99, 70.28, 69.55, 69.20, 69.02, 68.50, 67.93, 64.46, 63.57, 52.51, 50.90, 50.82, 40.36, 22.79; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₄F₂N₂NaO₁₄]⁺, 611.1870. found, 611.1861

Embodiment 21 Synthesis of Compound 22

This compound was prepared from Compound 26 and methyl trifluoroacetate, affording 22 (yield=76%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 5.92-5.82 (m, 1H), 5.35 (d, 1H, J=17.0 Hz), 5.26 (d, 1H, J=10.5 Hz), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.20-4.11 (m, 2H), 4.01 (dd, 1H, J₁=4.5 Hz, J₂=7.0 Hz), 4.00-3.91 (m, 3H), 3.86-3.72 (m, 5H), 3.65-3.51 (m, 4H), 3.50 (d, 1H, J=9.0 Hz), 2.65 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 1.95 (s, 3H), 1.60 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.07, 173.34, 159.38 (q, J_(F-C)=37.5 Hz), 133.59, 118.30, 116 (q, J_(F-C)=284.1 Hz), 100.40, 95.65, 72.63, 71.77, 69.62, 68.82 68.46, 68.29, 68.23, 66.97, 63.69, 62.68, 51.89, 50.75, 40.25 HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₃F₃N₂NaO₁₄]⁺, 629.1776. found, 629.1787

Embodiment 22 Synthesis of Compound 23

This compound was prepared from Compound 26 and chloroacetic acid, affording 23 (yield=54%). The synthetic procedure was the same as that of Compound 10.

¹H-NMR (500 MHz, D₂O) δ 6.01-5.92 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.27 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 4.95 (d, 1H, J=4.0 Hz, anomeric H of GalN), 4.24-4.18 (m, 3H), 4.16 (d, 1H, J=0.5 Hz), 4.08 (dd, 1H, J₁=5.0 Hz, J₂=8.0 Hz), 4.06-4.00 (m, 2H), 3.96 (dd, 1H, J₁=3.0 Hz, J₂=11.0 Hz), 3.92-3.80 (m, 4H), 3.70 (dd, 1H, J₁=2.0 Hz, J₂=8.5 Hz), 3.68-3.60 (m, 3H), 3.58 (dd, 1H, J₁=2.0 Hz, J₂=9.0 Hz), 2.72 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 1.83 (s, 3H), 1.56 (t, 1H, J=12.0 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.77, 174.12, 170.85, 134.33, 118.98, 101.12, 96.75, 73.33, 72.50, 70.34, 69.53, 69.21, 68.99, 68.21, 64.46, 63.36, 52.59, 51.11, 42.97, 40.99, 22.76; HRMS (m/z): [M+NH₄]⁺ calcd. for [C₂₂H₃₉ClN₃O₁₄]⁺, 604.2115. found, 604.2112

Embodiment 23 Synthesis of Compound 24

This compound was prepared from Compound 26 and methyl dichloroacetate, affording 24 (yield=54%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.35 (s, 1H), 6.01-5.92 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₂=17.5 Hz), 5.26 (d, 1H, J=10.5 Hz), 4.92 (d, 1H, J=4.0 Hz, anomeric H of GalN), 4.22 (dd, 1H, J₁=5.5 Hz, J₂=13.0 Hz), 4.17 (dd, 1H, J₁=3.5 Hz, J₂=6.0 Hz), 4.08 (dd, 1H, J₁=4.5 Hz, J₂=8.0 Hz), 4.05-4.00 (m, 2H), 3.98 (dd, 1H, J₁=3.0 Hz, J₂=11.0 Hz), 3.94-3.80 (m, 4H), 3.71 (dd, 1H, J₁=2.0 Hz, J₂=10.5 Hz), 3.69-3.62 (m, 3H), 3.58 (dd, 1H, J₁=1.5 Hz, J₂=8.5 Hz), 2.73 (dd, 1H, J₁=5.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (s, 3H), 1.69 (t, 1H, J=12.0 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 175.77, 174.06, 168.02, 134.28, 119.15, 101.09, 96.40, 73.34, 72.48, 70.36, 69.60, 69.24, 69.00, 68.96, 68.03, 66.77, 64.44, 63.38, 52.59, 51.64, 40.96, 22.77; HRMS (m/z): [M+H]⁺ calcd. for [C₂₂H₃₅Cl₂N₂O₁₄]⁺, 621.1460. found, 621.1477

Embodiment 24 Synthesis of Compound 25

Compound 54 (For its synthesis, see Embodiment 45) (145 mg, 0.176 mmol) was dissolved in 8.0 ml methanol, NaOMe/MeOH (30%, 0.02 g, 0.11 mmol) was added. The mixture was stirred at R.T. for 2 h. The mixture was concentrated in vacuum. The solution of NaOH in water (1N, 3 mL) was added. The mixture was stirred at R.T. for 24 h. The reaction mixture was neutralized with 1N HCl/MeOH to pH=3. The mixture was concentrated in vacuum. The residue was purified on a Biogel P-2 column with water as the eluent. Fractions containing the expected product were collected to afford 25 (yield=100%).

¹H-NMR (500 MHz, D₂O) δ 6.02-5.94 (m, 1H), 5.35 (ddd, 1H, J₁=1.5 Hz, J₂=3.0 Hz, J₃=17.5 Hz), 5.26 (ddd, 1H, J₁=1.0 Hz, J₂=2.5 Hz, J₃=10.5 Hz), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalN₃), 4.21 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.14 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.08-3.99 (m, 3H), 3.93-3.88 (m, 4H), 3.80 (dd, 1H, J₁=2.0 Hz, J₂=9.0 Hz), 3.72-3.64 (m, 2H), 3.64-3.58 (m, 2H), 3.47 (dd, 1H, J₁=J₂=10.0 Hz), 2.72 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, siaH-3 eq), 2.03 (s, 3H), 1.68 (t, 1H, J=12.5 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.33, 173.99, 134.42, 118.80, 101.11, 96.98, 73.27, 72.67, 70.28, 70.13, 69.46, 69.29, 69.25, 68.28, 64.58, 63.49, 63.33, 50.60, 40.80, 22.66; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₀H₃₂N₄NaO₁₃]⁺, 559.1858. found, 559.1851

Embodiment 25 Synthesis of Compound 26

Compound 25 (94 mg, 0.176 mmol. For its synthesis, see Embodiment 24) was dissolved in solution comprising of 15 ml pyridine, 10 ml TEA and 5 ml water, H₂S was introduced. The reaction mixture was stirred for 10 h. The mixture was concentrated in vacuum. The residue was purified on a Biogel P-2 column with water as the eluent. Fractions containing the expected product were collected to afford 26 (yield=67%).

¹H-NMR (500 MHz, D₂O) δ 6.02-5.97 (m, 1H), 5.38 (d, 1H, J=17.0 Hz), 5.28 (d, J=10.0 Hz), 5.17 (d, 1H, J=3.5 Hz, anomeric H of GalNH₂), 4.28 (dd, 1H, J₁=5.5 Hz, J₂=12.5 Hz), 4.14-4.00 (m, 4H), 3.93-3.80 (m, 4H), 3.71-3.56 (m, 5H), 3.48 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 2.73 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.03 (s, 3H), 1.68 (t, 1H, J=12.0 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.61, 173.94, 133.74, 119.33, 100.95, 94.97, 73.16, 72.34, 70.29, 69.56, 68.74, 68.56, 67.10, 64.04, 63.16, 52.40, 51.36, 40.78, 22.58; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₀H₃₄N₂NaO₁₃]⁺, 533.1953. found, 533.1957

Embodiment 26 Synthesis of Compound 27

This compound was prepared from Compound 50 [allyl 4-O-(5-amino-3,5-dideoxy-α-D-neuraminopyranosyl)-2-amino-2-deoxy-α-D-galactopyranoside. For its synthesis, see embodiment 43] and propionic anhydride, affording 27 (yield=55%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.01-5.92 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.26 (dd, 1H, J₁=1.5 Hz, J₃=10.5 Hz), 4.91 (d, 1H, J=4.0 Hz, anomeric H of GalN), 4.22 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.07 (dd, 1H, J₁=5.0 Hz, J₂=8.0 Hz), 4.03-4.00 (m, 2H), 3.96-3.81 (m, 5H), 3.75-3.62 (m, 4H), 3.56 (dd, 1H, J₁=1.5 Hz, J₂=9.0 Hz), 2.73 (dd, 1H, J₁=5.0 Hz, J₂=12.5 Hz, siaH-3 eq), 2.30 (q, 4H, J=7.5 Hz), 1.68 (t, 1H, J=12.5 Hz, siaH-3ax), 1.17 (t, 6H, J=7.5 Hz); ¹³C-NMR (75 MHz, D₂O) δ 134.13, 118.69, 100.91, 96.74, 73.14, 72.30, 70.09, 69.26, 69.05, 68.79, 68.68, 68.00, 64.32, 63.11, 52.25, 50.29, 40.89, 29.79, 29.64, 10.10, 10.07; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₄H₄₀N₂NaO₁₄]⁺, 603.2372. found, 603.2378.

Embodiment 27 Synthesis of Compound 28

This compound was prepared from Compound 50 and n-butyric anhydride, affording 28 (yield=56%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (300 MHz, D₂O) δ 5.83-5.68 (m, 1H), 5.35 (d, 1H, J=17.5 Hz), 5.26 (d, 1H, J=10.5 Hz), 4.72 (d, 1H, J=3.6 Hz, anomeric H of GalN), 4.05-3.36 (m, 15H), 2.53 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.07 (t, 3H, J=7.2 Hz), 1.49 (t, 1H, J=12.3 Hz, siaH-3ax), 1.42 (hexad peaks, 4H, J=7.2 Hz), 0.71 (t, 6H, J=7.2 Hz); ¹³C-NMR(125 MHz, D₂O) δ 178.89, 178.41, 174.141, 134.32, 118.98, 101.12, 97.01, 73.35, 72.50, 70.28, 69.53, 69.26, 69.10, 68.83, 68.14, 64.48, 63.33, 52.50, 50.53, 41.13, 38.59, 38.36, 19.74, 13.54, 13.42; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₆H₄₄N₂NaO₁₄]⁺, 631.2685. found, 631.2675

Embodiment 28 Synthesis of Compound 29

This compound was prepared from Compound 50 and i-butyric anhydride, affording 29 (yield=60%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.02-5.91 (m, 1H), 5.35 (dd, 1H, J₁=1.5 Hz, J₂=17.5 Hz), 5.26 (dd, 1H, J₁=1.0 Hz, J₃=10.5 Hz) 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.22 (dd, 1H, J₁=5.5 Hz, J₂=13.0 Hz), 4.14 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.07 (dd, 1H, J₁=4.5 Hz, J₂=7.5 Hz), 4.04-4.00 (m, 2H), 3.94-3.86 (m, 5H), 3.73-3.62 (m, 4H), 3.52 (dd, 1H, J₁=1.5 Hz, J₂=9.0 Hz), 2.74 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 2.56 (heptad peaks, 1H, J=7.0 Hz), 2.46 (heptad peaks, 1H, J=7.0 Hz), 1.68 (t, 1H, J=12.5 Hz, siaH-3ax), 1.13-1.09 (m, 12H); ¹³C-NMR (125 MHz, D₂O) δ 182.93, 182.46, 174.17, 134.32, 119.01, 101.13, 96.91, 73.37, 72.49, 70.30, 69.51, 69.28, 69.08, 68.72, 68.11, 64.49, 63.31, 52.36, 50.43, 41.17, 35.96, 35.71, 19.71, 19.61, 19.18 (2C); HRMS (m/z): [M+Na]⁺ calcd. for [C₂₆H₄₄N₂NaO₁₄]⁺, 631.2685. found, 631.2673

Embodiment 29 Synthesis of Compound 30

This compound was prepared from Compound 50 and caproic anhydride, affording 30 (yield=77%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.01-5.91 (m, 1H), 5.35 (dd, 1H, J₁=17.0 Hz, J₂=1.0 Hz), 5.26 (d, 1H, J₁=10.5 Hz), 4.91 (d, 1H, J=3.5 Hz), 4.21 (dd, 1H, J₁=5.5 Hz, J₂=13.0 Hz), 4.16 (dd, 1H, J₁=5.5 Hz, J₂=13.0 Hz), 4.07 (dd, 1H, J₁=4.0 Hz, J₂=8.0 Hz), 4.02-3.99 (m, 2H), 3.93-3.79 (m, 5H), 3.71-3.61 (m, 4H), 3.55 (d, 1H, J=7.0 Hz), 2.72 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, siaH-3 eq), 2.31-2.25 (m, 4H), 1.68 (t, 1H, J=12.5 Hz siaH-3ax), 1.62-1.57 (m, 4H), 1.36-1.24 (m, 8H), 0.86 (m, 6H); ¹³C-NMR(125 MHz, D₂O) δ 178.94, 178.48, 173.36, 134.11, 118.81, 100.51, 96.85, 73.28, 72.10, 70.08, 69.38, 69.10, 68.98, 68.40, 67.96, 64.35, 63.31, 52.27, 50.34, 40.68, 36.46, 36.26, 31.08, 30.96, 25.66, 22.25, 13.78; HRMS (m/z): [M+H]⁺ calcd. for [C₃₀H₅₃N₂O₁₄]⁺, 665.3491. found, 665.3495

Embodiment 30 Synthesis of Compound 31

This compound was prepared from Compound 50 and methyl fluoroacetate, affording 31 (yield=67%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 5.90-5.85 (m, 1H), 5.27 (dd, 1H, J₁=1.5 Hz, J₂=17.0 Hz), 5.27 (d, 1H, J=10.5 Hz), 4.87 (d, 1H, J=3.0 Hz, anomeric H of GalN), 4.8 (d, 2H, J_(F-H)=46.0 Hz), 4.7 (d, 2H, J_(F-H)=46.0 Hz), 4.17 (dd, 1H, J₁=4.0 Hz, J₂=10.5 Hz), 4.13 (dd, 1H, J₁=5.0 Hz, J₂=12.5 Hz), 4.00 (dd, 1H, J₁=4.0 Hz, J₂=8.0 Hz), 3.96-3.72 (m, 8H), 3.65 (ddd, 1H, J₁=4.5 Hz, J₂=10.0 Hz, J₃=12.0 Hz), 3.57-3.49 (m, 2H), 3.50 (dd, 1H, J₁=1.5 Hz, J₂=9.0 Hz), 2.72 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 1.79 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.36, 171.5 (d, 1C, J_(F-C)=18.12 Hz), 171.1 (d, 1C, J_(F-C)=18.62 Hz), 133.65, 118.22, 100.44, 96.19, 80 (d, 1C, J_(F-C)=189.53 Hz), 79 (d, 1C, J_(F-C)=179.56 Hz), 72.21, 71.87, 69.62, 68.79, 68.51, 68.149, 68.08, 67.40, 63.77, 62.66, 51.50, 49.58, 40.27; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₂F₄N₂NaO₁₄]⁺, 611.1870. found, 611.1872

Embodiment 31 Synthesis of Compound 32

This compound was prepared from Compound 50 and methyl difluoroacetate, affording 32 (yield=72%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.10 (t, 1H, J_(F-H)=53.6 Hz), 6.09 (dd, 1H, J_(F-H)=53.6 Hz), 5.92-5.86 (m, 1H), 5.30 (d, 1H, J=17.5 Hz), 5.18 (d, 1H, J=10.5 Hz), 4.91 (d, 1H, J=3.5 Hz, anomeric H of Gal), 4.20-4.13 (m, 2H), 4.02 (dd, 1H, J₁=4.5 Hz, J₃=8.0 Hz), 4.00-3.78 (m, 9H), 3.71-3.65 (m, 1H), 3.58-3.54 (m, 1H), 3.49 (d, 1H, J=9.0 Hz), 2.67 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 1.69 (dd, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 173.33, 165.3 (m, 2C), 133.61, 118.26, 108.29 (t, 1C, J_(F-C)=46.5 Hz), 108.17 (t, 1C, J_(F-C)=5.6 Hz), 100.45, 95.86, 71.99, 71.91, 69.63, 68.81, 68.48, 68.16, 68.02, 67.21, 63.78, 51.91, 50.14, 40.24; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₂F₄N₂NaO₁₄]⁺, 647.1682. found, 647.1669

Embodiment 32 Synthesis of Compound 33

This compound was prepared from Compound 50 and methyl trifluoroacetate, affording 33 (yield=49%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.01-5.92 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.26 (dd, 1H, J₁=1.5 Hz, J₃=10.5 Hz), 5.01 (d, 1H, J=4.0 Hz, anomeric H of GalN), 4.21-4.27 (m, 2H), 4.11 (dd, 1H, J₁=4.0 Hz, J₂=8.0 Hz), 4.07-3.86 (m, 8H), 3.76 (ddd, 1H, J₁=4.5 Hz, J₂=9.5 Hz, J₃=12.0 Hz), 3.67-3.61 (m, 2H), 3.56 (dd, 1H, J₁=1.5, J₂=9.0 Hz), 2.76 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 1.72 (t, 1H, J=12.5 Hz, siaH-3ax); ¹³C-NMR(125 MHz, D₂O) δ 174.04, 160.1 (m, 2C), 134.28, 119.01, 116.51 (dd, 2C, J_(F-H)=285.12 Hz), 101.18, 96.36, 72.66, 72.51, 70.35, 69.54, 69.19, 68.91, 68.65, 67.68, 64.53, 63.32, 53.13, 51.46, 40.99; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₀F₆N₂NaO₁₄]⁺, 683.1493. found, 683.1501

Embodiment 33 Synthesis of Compound 34

This compound was prepared from Compound 50 and chloroacetic acid, affording 34 (yield=60%). The synthetic procedure was the same as that of Compound 10.

¹H-NMR (500 MHz, D₂O) δ 6.02-5.93 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.27 (dq, 1H, J=1.5 Hz, 10.5 Hz), 4.97 (d, 1H, J=4.0 Hz, anomeric H of GalN), 4.21-4.18 (m, 2H), 4.19-4.17 (m, 3H), 4.09 (dd, 1H, J₁=4.0 Hz, J₃=8.5 Hz), 4.06-4.01 (m, 2H), 3.93-3.86 (m, 5H), 3.78 (ddd, 1H, J₁=4.5 Hz, J₂=9.5 Hz, J₃=12.0 Hz), 3.68 (dd, 1H, J₁=4.5 Hz, J₃=10.5 Hz), 3.65 (dd, 1H, J₁=6.5 Hz, J₃=12.0 Hz), 3.58 (dd, 1H, J₁=1.5 Hz, J₃=9.0 Hz), 2.71 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 1.75 (t, J=12.0 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 173.29, 171.20, 170.86, 134.33, 118.98, 100.58, 96.79, 73.10, 72.24, 70.31, 69.57, 69.24, 68.98, 68.46, 68.21, 64.52, 63.49, 52.97, 51.09, 43.05, 42.97, 40.62; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₄Cl₂N₂NaO₁₄]⁺, 643.1279. found, 643.1306

Embodiment 34 Synthesis of Compound 35

This compound was prepared from Compound 50 and methyl dichloroacetate, affording 35 (yield=43%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.35 (s, 1H), 6.32 (s, 1H), 6.01-5.92 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.26 (dq, 1H, J=1.5 Hz, 10.5 Hz), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.22 (ddt, 1H, J₁=J₂=1.5 Hz, J₃=5.5 Hz, J₄=13.0 Hz), 4.18 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.10 (dd, 1H, J₁=4.5 Hz, J₂=8.0 Hz), 4.08-3.84 (m, 8H), 3.75 (ddd, 1H, J₁=4.5 Hz, J₂=9.0 Hz, J₃=12.0 Hz), 3.66-3.61 (m, 2H), 3.57 (dd, 1H, J₁=1.5 Hz, J₂=9.5 Hz), 2.74 (dd, 1H, J₁=5.0 Hz, J₂=12.5 Hz, siaH-3 eq), 1.69 (t, 1H, J=12.0 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 173.99, 168.21, 168.04, 134.29, 119.14, 101.10, 96.41, 72.89, 72.65, 70.37, 69.60, 69.25, 69.08, 68.67, 68.03, 66.96, 66.76, 64.52, 63.36, 53.32, 51.64, 41.04; HRMS (m/z): [M+H]⁺ calcd. for [C₂₂H₃₃Cl₄N₂O₁₄]⁺, 689.0680. found, 689.0671

Embodiment 35 Synthesis of Compound 36

This compound was prepared from Compound 50 and methyl trichloroacetate, affording 36 (yield=64%). The synthetic procedure was the same as that of Compound 7.

¹H-NMR (500 MHz, D₂O) δ 6.01-5.91 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.26 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 5.01 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.25 (ddt, 1H, J₁=J₂=1.5 Hz, J₃=5.0 Hz, J₄=13.0 Hz), 4.20 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.14-3.80 (m, 10H), 3.66 (dd, 1H, J₁=4.0 Hz, J₂=11.0 Hz), 3.63 (dd, 1H, J₁=6.5 Hz, J₂=11.5 Hz), 3.59 (dd, 1H, J₁=1.5 Hz, J₂=9.5 Hz), 2.76 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, siaH-3 eq), 1.72 (t, 1H, J₁=J_(2=12.5) Hz, siaH-3ax); ¹³C-NMR(75 MHz, D₂O) δ 173.96, 165.38, 134.06, 119.05, 100.98, 96.14, 72.60, 72.46, 70.26, 69.47, 69.18, 69.18, 69.01, 68.27, 67.56, 64.41, 63.14, 54.42, 52.84, 41.14; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₀Cl₆N₂NaO₁₄]⁺, 778.9720. found, 778.9698

Embodiment 36 Synthesis of Compound 37

Compound 39 (For its synthesis, see Embodiment 38) (18.0 mg, 0.032 mmol) was dissolved in 5 ml methanol, 50% NH₂OH/water (0.5 mL, 7.57 mmol) and KCN (1.0 mg, 0.016 mmol) were added. The mixture was stirred at R.T. for 20 h. The mixture was concentrated in vacuum. The residue was purified by C18 reverse-phase column chromatography with MeOH/water as eluent and then on a on a Biogel P-2 column with water as the eluent, affording 37 (yield=50%).

¹H-NMR (500 MHz, D₂O) δ 6.01-5.93 (m, 1H), 5.36 (d, 1H, J₁=17.0 Hz), 5.26 (d, 1H, J₁=10.5 Hz), 4.92 (d, 1H, J=4.0 Hz, anomeric H of GalN), 4.20 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.15 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.06 (dd, 1H, J₁=4.0 Hz, J₂=8.0 Hz), 4.04-3.98 (m, 2H), 3.96-3.82 (m, 5H), 3.79-3.72 (m, 2H), 3.71-3.62 (m, 3H), 2.73 (dd, 1H, J₁=4.5 Hz, J₂=13.5 Hz, siaH-3 eq), 2.03 (s, 6H), 1.83 (t, 1H, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.64, 175.22, 166.20, 134.26, 118.61, 100.03, 96.91, 74.23, 71.78, 70.02, 69.34, 69.08, 68.28, 68.14, 67.62, 63.76, 63.44, 52.16, 50.41, 39.13, 22.64, 22.52; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₇N₃NaO₁₄]⁺, 590.2168. found, 590.2163

Embodiment 37 Synthesis of Compound 38

Compound 39 (For its synthesis, see Embodiment 38) (10.0 mg, 0.017 mmol) was dissolved in 2 ml methanol, NaBH₄ (6.0 mg, 0.158 mmol) was added in three batches. The mixture was stirred at R.T. for 1 h. The mixture was concentrated in vacuum. The residue was purified by C18 reverse-phase column chromatography with MeOH/water as eluent and then on a on a Biogel P-2 column with water as the eluent, affording 38 (yield=94%).

¹H-NMR (500 MHz, D₂O) δ 6.02-5.92 (m, 1H), 5.34 (dd, 1H, J₁=1.5 Hz, J₂=12.5 Hz), 5.25 (d, 1H, J=10.5 Hz), 4.94 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.21 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.16 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.08-4.00 (m, 3H), 3.95-3.78 (m, 8H), 3.74-3.68 (m, 2H), 3.62 (dd, 1H, J₁=6.0 Hz, J₂=12.0 Hz), 3.52 (d, 1H, J=9.0 Hz), 2.30 (dd, 1H, J₁=5.5 Hz, J₂=13.5 Hz, siaH-3 eq), 2.04 (s, 3H), 2.03 (s, 3H), 1.75 (t, 1H, J=13.0 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 177.44, 177.09, 136.14, 120.44, 102.79, 98.77, 74.09, 73.07, 72.25, 71.21, 71.04, 70.80, 70.25, 70.08, 65.59, 63.56, 62.79, 54.69, 52.33, 38.67, 24.54, 24.38. HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₈N₂NaO₁₃]⁺, 561.2266. found, 561.2267

Embodiment 38 Synthesis of Compound 39

Compound 48 (For its synthesis, see Embodiment 42) (100 mg, 0.119 mmol) was dissolved in 10 ml methanol, NaOMe/MeOH (30%, 0.02 g, 011 mmol) was added. The mixture was stirred at R.T. for 4 h. The reaction mixture was neutralized with 1N HCl/MeOH to pH=6. The mixture was concentrated in vacuum. The residue was purified by C18 reverse-phase column chromatography with MeOH/water as the eluent. Fractions containing the expected product were collected to afford 39 (yield=95%).

¹H-NMR (500 MHz, D₂O) δ 6.02-5.92 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.27 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 4.92 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.21-4.14 (m, 2H), 4.06-3.96 (m, 4H), 3.93-3.83 (m, 8H), 3.7 (ddd, 1H, J₁=4.5 Hz, J₂=10.0 Hz, J₃=12.0 Hz), 3.71-3.64 (m, 2H), 3.56 (d, 1H, J=9.5 Hz), 2.71 (dd, 1H, J₁=4.5 Hz, J₃=13.0 Hz, siaH-3 eq), 2.04 (s, 6H), 1.83 (t, J₁=J₂=12.5 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.70, 175.36, 170.58, 134.36, 118.79, 99.64, 97.06, 73.62, 71.30, 70.10, 69.51, 69.25, 69.01, 68.31, 67.89, 64.55, 63.85, 54.16, 52.44, 50.53, 39.83, 22.82, 22.64; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₃H₃₈N₂NaO₁₄]⁺, 589.2215. found, 589.2223

Embodiment 39 Synthesis of Compound 40

This compound was prepared from Compound 61 (For its synthesis, see Embodiment 47), affording 40 (yield=95%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.04-5.95 (m, 1H), 5.38 (dq, 1H, J=1.5 Hz, 17.5 Hz), 5.28 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 4.97 (d, 1H, J=3.5 Hz, anomeric H of Gal), 4.21 (ddd, 1H, J₁=1.0 Hz, J₂=5.5 Hz, J₃=13.0 Hz), 4.16 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 4.10-4.02 (m, 2H), 3.98 (d, 1H, J=2.5 Hz), 3.96-3.60 (m, 9H), 3.58 (dd, 1H, J₁=1.5 Hz, J₂=8.5 Hz), 2.72 (dd, 1H, J₁=4.5 Hz, J₃=13.0 Hz, siaH-3 eq), 2.03 (s, 3H), 1.74 (t, J=12.5 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.76, 173.21, 134.35, 119.10, 100.47, 98.31, 73.45, 72.13, 70.07, 70.00, 69.54, 69.02, 68.85, 68.63, 64.45, 63.51, 52.55, 40.56, 22.80; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₀H₃₃NNaO₁₄]⁺, 534.1793. found, 534.1789

Embodiment 40 Synthesis of Compound 41

This compound was prepared from Compound 63 (For its synthesis, see Embodiment 48), affording 41 (yield=95%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.01-5.92 (m, 1H), 5.35 (dq, 1H, J=1.5 Hz, 17.0 Hz), 5.28 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 4.97 (d, 1H, J=3.5 Hz, anomeric H of GlcNAc), 4.21 (ddd, 1H, J₁=1.5 Hz, J₂=5.0 Hz, J₃=13.0 Hz), 4.02 (ddd, 1H, J₁=1.5 Hz, J₂=6.0 Hz, J₃=13.0 Hz), 3.98 (dd, 1H, J₁=5.0 Hz, J₂=10.5 Hz), 3.93 (dd, 1H, J₁=4.0 Hz, J₂=10.5 Hz), 3.91-3.79 (m, 4H), 3.78-3.61 (m, 5H), 3.59 (dd, 1H, J₁=1.5 Hz, J₂=9.0 Hz), 3.53 (dd, 1H, J₁=9.5 Hz, J₂=10.0 Hz), 2.75 (dd, 1H, J₁=4.5 Hz, J₂=12.0 Hz, siaH-3 eq), 2.04 (s, 3H), 1.71 (t, J=12.0 Hz, siaH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 175.80, 175.16, 174.15, 134.32, 118.80, 100.89, 96.77, 73.24, 72.51, 71.75, 71.32, 70.68, 69.38, 69.00, 63.56, 63.36, 54.31, 52.63, 40.87, 22.76, 22.58; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₂H₃₆N₂NaO₁₄]⁺, 575.2059. found, 575.2067

Embodiment 41 Synthesis of Compound 42

This compound was prepared from Compound 49 (For its synthesis, see Embodiment 42), affording 42 (yield=95%). The synthetic procedure was the same as that of Compound 3.

¹H-NMR (500 MHz, D₂O) δ 6.02-5.94 (m, 1H), 5.35 (dd, 1H, J₁=17.0 Hz,), 5.26 (d, 1H, J₁=10.5 Hz), 4.95 (d, 1H, J=3.5 Hz, anomeric Hon GalNAc), 4.21 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz), 4.18 (dd, 1H, J₁=4.5 Hz, J₂=8.5 Hz), 4.11-4.02 (m, 4H), 3.93-3.83 (m, 5H), 2.75 (dd, 1H, J₁=5.5 Hz, J₂=10.0 Hz), 3.76 (dd, 1H, J₁=5.5 Hz, J₂=12.0 Hz), 3.56 (d, 1H, J=9.0 Hz), 3.47 (dd, 1H, J₁=8.5 Hz, J₂=10.0 Hz), 2.39 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, sialH-3 eq), 2.05 (s, 3H), 2.04 (s, 3H), 1.68 (dd, 1H, J₁=12.5 Hz, J₂=12.0 Hz, sialH-3ax); ¹³C-NMR (125 MHz, D₂O) δ 177.45, 177.20, 174.52, 136.43, 120.45, 101.42, 99.08, 73.28, 72.59, 72.01, 71.44, 71.27, 70.52, 70.24, 69.11, 65.92, 65.00, 54.50, 52.45, 41.92, 24.70, 24.53; HRMS (m/z): [M+Na]⁺ calcd. for C₂₂H₃₆N₂NaO₁₄, 575.2059. found, 575.2050

Embodiment 42 Synthesis of Compound 48 and 49

Compound 46 (1.07 g, 2.93 mmol, 1.00 eq. For its synthesis, see U.S. Pat. No. 6,013,779.) and Compound 47 (2.06 g, 3.38 mmol, 1.15 eq. For its synthesis, see J. Org. Chem. 2000, 65, 144-151.) were added into the 100 mL double-necked flask together with activated molecular sieves. Under argon atmosphere, 40 mL THF was added. The mixture was stirred at R.T. for 0.5 h and then was cooled to −72° C. To the mixture, TMSOTf (70 μL, 0.36 mmol, 0.11 eq.) was added in three batches during 15 min. The reaction went to completion in 4 h (by TLC monitoring). TEA (1.0 mL) was added. The mixture was filtered through diatomite. The filtrate was concentrated in vacuum. The residue was purified on silica gel, affording 48 and 49 (48:49=1:1.2, yield=84%).

Compound 48: ¹H-NMR (500 MHz, CDCl₃) δ 8.08-8.05 (m, 2H), 7.60-7.50 (m, 1H), 7.50-7.40 (m, 2H), 5.97-5.87 (m, 1H), 5.75 (d, 1H, J=10.0 Hz, NHAc), 5.42 (d, 1H, J=10.0 Hz, NHAc), 5.40-5.31 (m, 3H), 5.29 (dd, 1H, J₁=3.0 Hz, J₂=11.0 Hz), 5.23 (ddd, 1H, J₁=1.0 Hz, J₂=3.0 Hz, J₃=10.5 Hz), 4.96 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.92-4.85 (m, 2H), 4.36 (dd, 1H, J₁=2.5 Hz, J₂=12.5 Hz), 4.25-4.20 (m, 2H), 4.18-4.00 (m, 5H), 3.88 (dd, 1H, J₁=5.5 Hz, J₂=10.0 Hz), 3.80 (s, 3H), 3.75 (dd, 1H, J₁=7.0 Hz, J₂=10.0 Hz), 3.02 (d, 1H, J=3.0 Hz, OH), 2.59 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, sialH-3 eq), 2.14 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.01 (s, 3H, OAc), 1.98 (t, 1H, J=13.0 Hz, sialH-3ax), 1.97 (s, 3H, OAc), 1.88 (s, 3H, NAc), 1.87 (s, 3H, NAc); ¹³C-NMR (125 MHz, CDCl₃) δ 170.93, 170.86, 170.25, 170.18, 170.15, 169.92, 168.03, 166.67, 133.53, 133.31, 129.92, 129.52, 128.46, 117.90, 98.70, 96.96, 72.78, 72.19, 69.10, 69.03, 68.68, 68.36, 67.40, 66.89, 62.96, 62.54, 23.30, 23.13, 21.03, 20.82, 20.77, 20.63. HRMS (m/z): [M+Na]⁺ calcd. for [C₃₈H₅₀N₂NaO₁₉]⁺, 861.2900. found, 861.2903

Compound 49: ¹H-NMR (500 MHz, CDCl₃) δ 8.12-8.08 (m, 2H), 7.60-7.52 (m, 1H), 7.47-7.40 (m, 2H), 5.96-5.84 (m, 2H), 5.62 (d, 1H, J=10.0 Hz, NHAc), 5.44-5.28 (m, 5H), 5.23 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 4.94 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.85 (ddd, 1H, J₁=4.0 Hz, J₂=10.0 Hz, J₃=11.0 Hz), 4.78 (dd, 1H, J₁=2.0 Hz, J₂=12.5 Hz), 4.40-4.32 (m, 2H), 4.21 (ddt, 1H, J₁=J₂=1.0 Hz, J₃=5.0 Hz, J₄=12.5 Hz), 4.16 (dd, 1H, J₁=8.0 Hz, J₂=12.5 Hz), 4.11 (dd, 1H, J₁=5.0 Hz, J₂=8.5 Hz), 4.02-3.96 (dd, 1H, J₁=6.0 Hz, J₂=12.0 Hz), 3.88 (t, 1H, J₁=J₂=9.0 Hz), 3.82 (s, 3H), 3.82-3.72 (m, 1H), 3.57 (d, 1H, J=4.0 Hz, OH), 3.50 (dd, 1H, J₁=5.0 Hz, J₂=9.0 Hz), 2.51 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, sialH-3 eq), 2.14 (s, 3H, OAc), 2.16-2.10 (1H, overlapped, sialH-3ax), 2.11 (s, 3H, OAc), 2.05 (s, 3H, OAc), 1.98 (s, 3H, OAc), 1.85 (s, 3H, NAc), 1.80 (s, 3H, NAc); ¹³C-NMR (125 MHz, CDCl₃) δ 171.43, 170.77, 170.47, 170.00, 167.13, 166.73, 133.54, 133.31, 129.97, 129.44, 128.40, 117.63, 98.29, 97.08, 72.07, 71.59, 70.95, 68.88, 68.38, 68.23, 68.11, 66.46, 62.45, 61.57, 52.77, 49.90, 47.83, 37.41, 23.19, 23.14, 21.09, 20.85, 20.81, 20.75. HRMS (m/z): [M+Na]⁺ calcd. for [C₃₈H₅₀N₂NaO₁₉]⁺, 861.2900. found, 861.2882

Embodiment 43 Synthesis of Compound 50

Compound 48 (100 mg, 0.119 mmol) was dissolved in 10 ml methanol (10 mg/mL), NaOMe/MeOH (30%, 0.02 g, 011 mmol) was added. The mixture was stirred at R.T. for 4 h. The mixture was heated to 90° C. and stirred for 8 h. The reaction mixture was neutralized with 1N HCl/MeOH to pH=4-7. The mixture was concentrated in vacuum. The residue was purified on a Biogel P-2 column with water as the eluent. Fractions containing the expected product were collected to afford 50 (yield=88%).

¹H-NMR (500 MHz, D₂O) δ 6.02-5.96 (m, 1H), 5.37 (ddd, 1H, J₁=1.5 Hz, J₂=3.0 Hz, J₃=17.5 Hz), 5.29 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 5.11 (d, 1H, J=3.5 Hz, anomeric H of GalN), 4.26 (dd, 1H, J₁=5.5 Hz, J₂=12.5 Hz), 4.09-4.05 (m, 2H), 3.99-3.96 (m, 2H), 3.93-3.88 (m, 3H), 3.80 (dd, 1H, J₁=2.0 Hz, J₂=9.0 Hz), 3.73-3.68 (m, 2H), 3.61 (dd, 1H, J₁=4.0 Hz, J₂=10.5 Hz), 3.57-3.54 (m, 1H), 3.38-3.35 (m, 1H), 2.95-2.91 (m, 1H), 2.72 (dd, 1H, J₁=4.5 Hz, J₂=12.5 Hz, sialH-3 eq), 1.64 (t, 1H, J=12.5 Hz, sialH-3ax); ¹³C-NMR (75 MHz, D₂O) δ 176.08, 135.91, 121.21, 102.96, 8.07, 76.19, 74.57, 72.38, 71.83, 71.58, 70.82, 70.60, 70.18, 66.26, 65.07, 54.99, 53.35, 42.87; HRMS (m/z): [M+Na]⁺ calcd. for [C₁₈H₃₂N₂NaO₁₂]⁺, 491.1847. found, 491.1852

Embodiment 44 Synthesis of Compound 52 and 55

These compounds were prepared from Compound 51 (For its synthesis, see U.S. Pat. No. 6,013,779) and Compound 46 (For its synthesis, see U.S. Pat. No. 6,013,779), affording 52 and 55 (52:55=2.6:1, yield=81%). The synthetic procedure was the same as that of Compound 48 and 49.

Compound 52: ¹H-NMR (500 MHz, CDCl₃) δ 8.08-8.04 (m, 2H), 7.60-7.52 (m, 1H), 7.50-7.39 (m, 2H), 7.10 (d, 1H, J=10.0 Hz, NHTFA), 5.98-5.87 (m, 1H), 5.78 (d, 1H, J=10.0 Hz, NHAc), 5.38-5.27 (m, 4H), 5.25 (dd, 1H, J₁=1.0 Hz, J₂=10.0 Hz), 5.23 (ddd, 1H, J₁=4.5 Hz, J₂=10.5 Hz, J₃=12.0 Hz), 4.96 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.88 (ddd, 1H, J₁=4.0 Hz, J₂=10.0 Hz, J₃=11.0 Hz), 4.38 (dd, 1H, J₁=2.0 Hz, J₂=12.5 Hz), 4.30 (dd, 1H, J₁=2.0 Hz, J₂=12.5 Hz), 4.25-4.20 (m, 2H), 4.08 (dd, 1H, J₁=6.0 Hz, J₂=12.5 Hz), 4.06-4.00 (m, 3H), 3.88 (dd, 1H, J₁=5.5 Hz, J₂=9.5 Hz), 3.80 (s, 3H, COOMe), 3.78 (dd, 1H, J₁=7.0 Hz, J₂=9.5 Hz), 3.08 (d, 1H, J=3.0 Hz, OH), 2.63 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, sialH-3 eq), 2.14 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.12 (s, 3H, OAc), 1.97 (t, 1H, J₁=J₂=12.5 Hz sialH-3ax), 1.99 (s, 3H, OAc), 1.96 (s, 3H, OAc), 1.88 (s, 3H, NAc); ¹³C-NMR (125 MHz, CDCl₃) δ 170.90, 170.86, 170.42, 170.13, 169.94, 167.86, 166.86, 157.59 (q, 1C, J=37.5 Hz, carbonyl in TFA) 133.51, 133.37, 129.89, 129.46, 128.46, 117.92, 115.05 (q, 1C, J=286.2 Hz, CF₃), 98.70, 96.96, 72.21, 71.99, 69.31, 68.71, 68.47, 68.38, 67.26, 66.84, 63.06, 62.38, 53.10, 49.91, 47.32, 37.10, 23.24, 21.00, 20.59, 20.57, 20.54; HRMS (m/z): [M+Na]⁺ calcd. for [C₃₈H₄₇F₃N₂NaO₁₉]⁺, 915.2617. found, 915.2615.

Compound 55: ¹H-NMR (500 MHz, CDCl₃) δ 8.10-8.04 (m, 2H), 7.56 (t, 1H, J=7.5 Hz), 7.43 (q, 2H, J=8.0 Hz), 5.98-5.87 (m, 1H), 5.88 (d, 1H, J=10.0 Hz, NHTFA), 5.42-5.28 (m, 4H), 5.25 (dd, 1H, J₁=1.0 Hz, J₂=10.0 Hz), 4.96 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.84 (ddd, 1H, J₁=4.0 Hz, J₂=10.0 Hz, J₃=11.0 Hz), 4.78 (dd, 1H, J₁=2.0 Hz, J₂=12.0 Hz), 4.46 (dd, 1H, J₁=2.0 Hz, J₂=10.5 Hz), 4.35 (br, 1H), 4.21 (dd, 1H, J₁=5.0 Hz, J₂=12.5 Hz), 4.14 (dd, 1H, J₁=8.0 Hz, J₂=12.0 Hz), 4.10 (dd, 1H, J₁=5.0 Hz, J₂=8.0 Hz), 4.00 (dd, 1H, J₁=5.5 Hz, J₂=12.5 Hz), 3.96-3.88 (m, 2H), 3.83 (s, 3H, COOMe), 3.58-3.50 (m, 2H), 3.45-3.87 (br, 1H), 2.54 (dd, 1H, J₁=5.0 Hz, J₂=13.0 Hz, sialH-3 eq), 2.26 (br, 1H) 2.13 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.05 (s, 3H, OAc), 1.99 (s, 3H, OAc), 1.96 (s, 3H, OAc), 1.86 (s, 3H, NAc), 1.86 (t, 1H, J₁=J₂=12.5 Hz, overlapped, sialH-3ax); ¹³C-NMR (75 MHz, CDCl₃) δ 171.56, 170.84, 170.64, 170.27, 170.20, 166.89, 157.76 (q, 1C, J=37.7 Hz, carbonyl in TFA), 133.48, 129.95, 129.29, 128.51, 117.87, 115.40 (q, 1C, J=285.7 Hz, CF₃) 98.30, 97.05, 72.09, 71.81, 70.57, 68.67, 68.48, 68.03, 67.88, 66.53, 62.31, 61.69, 52.92, 50.13, 47.70, 37.35, 23.22, 21.02, 20.79, 20.58; HRMS (m/z): [M+Na]⁺ calcd. for [C₃₈H₄₇F₃N₂NaO₁₉]⁺, 915.2617. found, 915.2626

Embodiment 45 Synthesis of Compound 54

This compound was prepared from Compound 47 (See Tetrahedron Lett. 1992, 33, 6123-6126) and Compound 53 (For its synthesis, see Embodiment 46), affording 54 (yield=58%). The synthetic procedure was the same as that of Compound 48.

¹H-NMR (500 MHz, CDCl₃) δ 8.14-8.10 (m, 2H), 7.62-7.56 (m, 1H), 7.50-7.39 (t, 2H, J=8.0 Hz), 6.00-5.91 (m, 1H), 5.49 (dd, 1H, J₁=3.5 Hz, J₂=11.0 Hz), 5.42-4.80 (m, 3H), 5.25 (dd, 1H, J₁=1.5 Hz, J₂=10.5 Hz), 5.22 (d, 1H, J=10.0 Hz, NHAc), 5.11 (d, 1H, J=3.5 Hz, anomeric H of GalNAc), 4.88 (ddd, 1H, J₁=4.5 Hz, J₂=9.5 Hz, J₃=12.0 Hz), 4.38 (dd, 1H, J₁=2.0 Hz, J₂=12.5 Hz), 4.36-4.33 (m, 1H), 4.28 (ddt, 1H, J₁=J₂=1.5 Hz, J₃=5.0 Hz, J₄=13.0 Hz), 4.13-3.97 (m, 6H), 3.87 (dd, 1H, J₁=5.5 Hz, J₂=9.5 Hz), 3.81 (s, 3H, COOMe), 3.78 (dd, 1H, J₁=7.0 Hz, J₂=9.5 Hz), 3.20 (d, 1H, J=4.5 Hz, OH), 2.57 (dd, 1H, J₁=4.5 Hz, J₂=13.0 Hz, sialH-3 eq), 2.12 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.02 (t, 1H, J₁=J₂=12.5 Hz sialH-3ax), 1.91 (s, 3H, OAc), 1.87 (s, 3H, NAc); ¹³C-NMR (75 MHz, CDCl₃) δ 171.00, 170.86, 170.45, 170.29, 170.11, 167.96, 165.66, 133.29, 133.15, 129.89, 129.46, 128.35, 117.85, 98.54, 97.13, 72.76, 71.55, 69.36, 68.91, 68.55, 68.45, 67.32, 66.78, 62.77, 62.54, 57.60, 52.98, 49.07, 36.70, 23.00, 20.97, 20.73, 20.66, 20.48; HRMS (m/z): [M+Na]⁺ calcd. for [C₃₆H₄₆N₄NaO₁₈]⁺, 845.2699. found, 845.2690

Embodiment 46 Synthesis of Compound 60 and 53

Compound 56 (For its synthesis, see Tetrahedron Lett. 2005, 46, 8993-8995)(7.91 g, 21.2 mmol) was dissolved in CH₂Cl₂ (66 mL), and AllylOH (7.0 mL, 102 mmol) and BF₃.Et₂O (25 mL, 197.5 mmol) was added. The mixture was heated under reflux for 3 h. BF₃.Et₂O (10 mL, 79 mmol) was added and the mixture was refluxed for another 3 h. The solvent was evaporated under reduced pressure, and the residue was neutralized with saturated KHCO₃ aq. The mixture was extracted with ethyl acetate (150 mL×3). The organic layer were collected, dried over anhydrous Na₂SO₄, and concentrated in vacuum. The residue was purified by column chromatography on silica gel (acetone:petroleum ether=1:6) to afford 57 (5.68 g). The anomeric isomers could not be separated, and were employed for the following reaction without further purification.

To a stirred solution of the above product 57 (4.82 g, 13.0 mmol) in methanol (70 mL) was added a sodium methoxide solution in methanol (30%, 0.5 g, 2.78 mmol). The mixture was stirred at R.T. for 0.5 h. The reaction mixture was neutralized with strongly acidic resin, which was filtered off later. The solvent was removed under reduced pressure to afford 58 (2.88 g, yield=91%).

To a solution of the above product 58 (2.88 g, 11.75 mmol) in MeCN (10 mL) was added PhCH(OMe)₂ (2.15 g, 14.13 mmol) and CSA (203 mg, 0.88 mmol). The mixture was stirred at R.T. for 18 h. After triethylamine (0.2 g, 2.0 mmol) was added, the mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel to afford 59 (2.78 g). The unstable a isomer was separated in this stage. The product employed for the following reaction was without complete purification.

The above product 59 (2.78 g, 8.35 mmol) and DMAP (70 mg, 0.6 mmol) were dissolved in pyridine (10 mL), and the solution was cooled on ice bath. BzCl (1.8 mL, 15 mmol) was added dropwise. The mixture was stirred at R.T. for 24 h. The solvent was evaporated under reduced pressure. The residue was neutralized with saturated KHCO₃ aq., and extracted with ethyl acetate (150 mL×3). The organic layer were collected, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (acetone:petroleum ether=1:5) to afford 60 (3.21 g, yield=88%).

Compound 60: ¹H-NMR (300 MHz, CDCl3) δ 8.14-8.07 (m, 2H), 7.63-7.55 (m, 1H), 7.48-7.43 (m, 4H), 7.37-7.33 (m. 3H), 6.02-5.95 (m, 1H), 5.60 (dd, 1H, J1=3.6 Hz, J2=11.1 Hz, H-3), 5.55 (s, 1H), 5.37 (dq, 1H, J1=1.5 Hz, 17.1 Hz, terminal H of vinyl in allyl), 5.26 (dd, 1H, J1=1.5 Hz, J2=10.2 Hz, terminal H of vinyl in allyl), 5.19 (d, 1H, J=3.0 Hz, anomeric H), 4.63 (d, 1H, J=2.7 Hz), 4.29 (dd, 1H, J1=2.5 Hz, J2=12.3 Hz, H-6a), 4.28 (ddt, 1H, J1=J2=1.5 Hz, J3=5.4 Hz, J4=13.0 Hz, —OCH2 in allyl), 4.16-4.08 (m, 3H), 3.90-3.86 (br, 1H), 13C-NMR (75 MHz, CDCl3) δ 171.89, 165.95, 137.44, 133.68, 133.44, 133.04, 130.13, 129.90, 129.29, 128.89, 128.74, 128.44, 128.08, 125.96, 118.20, 100.48, 97.50, 73.51, 70.05, 69.07, 68.83, 62.67, 57.53; HRMS (m/z): [M+Na]⁺ calcd. for [C₂₃H₂₃N₃NaO₆]⁺, 460.1479. found, 460.1488.

To a solution of Compound 60 (688 mg, 1.57 mmol, For its synthesis, see the foregoing two paragraphs) in MeOH (10 mL) was added strongly acidic resin (668 mg). The mixture was stirred at 40° C. for 4 h. The resin was filtered off, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (acetone:petroleum ether=1:3) to afford 53 (402 mg, yield=73%):

Compound 53: ¹H-NMR (500 MHz, CDCl₃) δ 8.09-8.05 (m, 2H), 7.60-7.55 (m, 1H), 7.46-7.42 (m, 2H), 5.97-5.88 (m, 1H), 5.45 (dd, 1H, J1=3.0 Hz, J2=11.0 Hz, H-3), 5.34 (dq, 1H, J1=1.5 Hz, J2=17.5 Hz, terminal H of vinyl in allyl), 5.24 (dq, 1H, J=1.5 Hz, J2=10.0 Hz, terminal H of vinyl in allyl), 5.08 (d, 1H, J=3.5 Hz, anomeric H), 4.39 (d, 1H, J=2.5 Hz, H-4), 4.22 (ddt, 1H, J1=J2=1.5 Hz, J3=6.5 Hz, J4=13.0 Hz, —OCH2 in allyl), 4.05 (ddt, 1H, J1=J2=1.5 Hz, J3=6.5 Hz, J4=13.0 Hz, —OCH2 in allyl), 4.00-3.94 (m, 2H), 3.91-3.81 (m, 2H), 3.55 (br, 1H, OH), 2.93 (br, 1H, OH); 13C-NMR (75 MHz, CDCl3) δ 165.74, 133.55, 133.04, 129.81, 129.10, 128.49, 118.03, 97.28, 71.61, 69.14, 68.73, 62.85, 57.45; HRMS (m/z): [M+Na]⁺ calcd. for [C₁₆H₁₉N₃NaO₆]⁺, 372.1166. found, 372.1158

Embodiment 47 Synthesis of Compound 61

This compound was prepared from Compound 47 and 62 (See Carbohydr. Res. 1994, 253, 167-183), affording 61 (yield=51%). The synthetic procedure was the same as that of Compound 48.

Compound 61: ¹H-NMR (500 MHz, D₂O) δ 8.05-7.98 (m, 4H), 7.53-7.48 (m, 2H), 7.40-7.35 (m, 4H), 5.90-5.81 (m, 1H), 5.73-5.67 (m, 2H), 5.40-5.26 (m, 5H), 5.16-5.12 (m, 1H), 4.90 (ddd, 1H, J1=4.5 Hz, J2=9.5 Hz, J3=11.5 Hz), 4.41-4.37 (m, 2H), 4.25 (ddt, 1H, J1=J2=1.5 Hz, J3=5.5 Hz, J4=13.5 Hz), 4.18 (t, 1H, J1=J2=6.0 Hz), 4.16-4.02 (m, 4H), 3.92 (dd, 1H, J1=5.5 Hz, J2=9.5 Hz), 3.82 (s, 3H, COOMe, overlapped), 3.84-3.80 (m, 1H, overlapped), 3.12 (b, 1H, OH), 2.59 (dd, 1H, J1=5.0 Hz, J2=13.0 Hz, sialH-3 eq), 2.14 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.02 (t, 1H, J1=J2=12.5 Hz sialH-3ax), 1.94 (s, 3H, OAc), 1.88 (s, 3H, NAc); 13C-NMR (125 MHz, CDCl3) δ 170.93, 170.27, 170.23, 170.19, 168.05, 165.99, 165.92, 133.57, 133.12, 129.79, 129.77, 129.66, 129.52, 128.33, 117.38, 98.70, 95.73, (77.25, 77.00, 76.74 CDCl3), 72.85, 71.13, 69.24, 68.96, 68.87, 68.51, 68.22, 67.65, 67.40, 62.93, 62.57, 53.03, 49.35, 36.98, 23.14, 21.04, 20.81, 20.76, 20.54; HRMS (m/z): [M+Na]⁺ calcd. for [C₄₃H₅₁NNaO₂₀]⁺, 924.2897. found, 924.2905

Embodiment 48 Synthesis of Compound 63

This compound was prepared from Compound 47 and 64 (See Monatshefte fuer Chemie. 2002, 133, 531-540), affording 63 (yield=51%). The synthetic procedure was the same as that of Compound 48.

Compound 63: ¹H-NMR (500 MHz, D₂O) δ 8.06-8.03 (m, 2H), 7.58-7.53 (m, 1H), 7.45-7.41 (m, 2H), 5.94-5.85 (m, 2H), 5.49-5.41 (m, 2H), 5.35-5.21 (m, 4H), 5.05-4.97 (m, 1H), 4.92 (d, 1H, J=4.0 Hz, anomeric H on GlcNAc), 4.45 (ddd, 1H, J1=4.0 Hz, J2=10.0 Hz, J3=11.0 Hz), 4.29-4.22 (m, 2H), 4.25 (ddt, 1H, J1=J2=1.5 Hz, J3=5.5 Hz, J4=12.5 Hz), 4.14 (dd, 1H, J1=1.5 Hz, J2=10.5 Hz), 4.10-3.96 (m, 4H), 3.81 (s, 3H, COOMe), 3.83-3.78 (1H, overlapped), 3.76 (dd, 1H, J1=1.5 Hz, J2=11.2 Hz), 3.44 (br., 1H, OH), 2.66 (dd, 1H, J1=5.0 Hz, J2=13.5 Hz, sialH-3 eq), 2.11 (s, 3H, OAc), 1.90-1.80 (1H, sial H-3ax, overlapped), 2.06 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.90 (s, 3H, OAc), 1.86 (s, 3H, NAc), 1.84 (s, 3H, NAc); 13C-NMR (125 MHz, CDCl3) δ 170.99, 170.60, 170.34, 170.05, 169.98, 169.56, 168.24, 167.34, 133.34, 133.22, 129.80, 129.58, 128.36, 118.00, 97.86, 96.74, 73.80, 72.22, 71.16, 68.85, 68.49, 68.37, 68.01, 67.11, 62.76, 62.18, 52.87, 51.86, 49.59, 37.77, 23.13, 23.09, 21.02, 20.87, 20.65, 20.27; HRMS (m/z): [M+Na]⁺ calcd. for C₃₈H₅₀N₂NaO₁₉, 861.2900. found, 861.2872

Embodiment 49 Synthesis of Glycoconjugates by Conjugation Reaction between Hapten 2-14, 16-24, 29-34, 42 and Carrier Protein/Peptide

The hapten (Compound 2, 10 mg) was dissolved in anhydrous methanol (2 mL). At −78° C., ozone was introduced into the mixture. When the color of the mixture turned blue (about 10˜30 min), the ozone was cut out. The color stayed blue for about 10 min. N₂ was then introduced into the flask to extrude the ozone in excess. Dimethylsulfide (0.5 mL) was added dropwise. The temperature was allowed to R.T. spontaneously. After 2 h, the solvent was removed in vacuum, affording the aldehyde derivative. The aldehyde derivative of the carbohydrate hapten and the protein (or polypeptide), such as BSA or KLH (10 mg), were dissolved in pH 7.2 buffer. NaBH₃CN (3 mg) was added. The reaction flask was placed on a shaking table and the mixture was shaken for 24 h. The mixture was dialyzed to afford the desired glycoconjugate STn-KLH.

According to aforementioned procedure, the compounds of Embodiment 3-47 (2-14, 16-24, 29-34, 42) are conjugated to the protein carrier to afford the corresponding glycoconjugates 3-KLH, 4-KLH, 5-KLH, 6-KLH, 7-KLH, 8-KLH, 9-KLH, 10-KLH, 11-KLH, 12-KLH, 14-KLH, 16-KLH, 17-KLH, 18-KLH, 19-KLH, 20-KLH, 21-KLH, 22-KLH, 23-KLH, 24-KLH, 29-KLH, 30-KLH, 31-KLH, 32-KLH, 33-KLH, 34-KLH, 42-KLH.

It should be noted that although the structurally typical R₁, R₂, R₃, R₄, R₅ and R₆ have been employed in the syntheses of STn derivatives and their conjugates with proteins (or polypeptides), the art described in the present invention can be applied to syntheses of structurally diverse R substituents, with R₁ being any acylamino, —NH₂, —N₃ or —OH group; R₂ any acylamino, —NH₂, —N₃, —OH group; R₃ equatorial or axial —CO₂H, —CH₂OH, —CO₂M, —C(O)NHOH, —H wherein M may be alkyl, aryl, heterocycle or cation); R₄ different linkers; R₅ equatorial or axial —OH; and R6 H or β-galactosyl. These synthetic tasks can be accomplished without any creative endeavor by the person in the art. It is obvious that the scope of the patent protection is not constrained with the limited compounds of the presented Embodiments.

Characterizing the Immune Response

-   1. Materials and resources: -   Test antigens: glycoproteins (or -polypeptides) prepared in     Embodiment 49 of the present invention. -   2. Test method: -   (1) Immunization of mice

Groups of six mice (female pathogen-free BALB/c, age 6-8 weeks, Number: SCXKjing2007-0001, SPF/VAF, from Department of Laboratory Animal Science, Peking University Health Science Center) were immunized four times at 2-week intervals with STn-KLH or modified STn-KLH glycoconjugates (each containing 2 μg of carbohydrate in PBS). The vaccines were administered intraperitoneally. Mice were bled prior to the initial vaccination, 13 days after the second and the third vaccinations, and 14 days after the fourth vaccination. Blood was clotted to obtain sera, which were stored at −80° C.

-   (2) Serological assays.     -   The total antigen-specific antibody titers of the pooled sera         were assessed by means of ELISA.     -   1 ELISA plate was coated with 100 μL of STn-BSA (including 0.02         μg of STn) overnight at 4° C. (0.1 M bicarbonate buffer,         pH=9.6).     -   2 After being washed three times (200 μL per time for per         microwell) with PBS-Tween20 (0.05%), microwells were blocked         with 3% BSA-PBS (200 μL per microwell) and incubated for 1 h at         37° C.     -   3 After the plate was washed for three times, serially diluted         sera (1% BSA-PBS, double diluted) were added to microwells (100         μL/well) and incubated for 1 h at 37° C.     -   4 The plate was washed for three times and incubated with 1:5000         dilution of horseradish peroxidase-conjugated goat anti-mouse         IgG (γ-chain specific) or IgM (μ-chain specific) (Southern         Biotechnology Associates, Inc., Buckingham, Ala.) for 1 h at 37°         C.     -   5 The plate was washed for three times, developed with         o-phenylenediamine (OPD) substrate in the dark for 15 min         terminated by addition of 2M H₂SO₄.     -   6 The OD value is read at 490 nm on the Microplate reader. The         antibody titer was defined as the highest dilution showing an         absorbance of 0.1, after subtracting background. -   (3) Result -   1)

TABLE 1 Table 1. ELISA titers anti-STn 13 days after the second vaccination Group IgG IgM immunized with STn-KLH 910 <1000 immunized with 3-KLH <1000 <1000 immunized with 4-KLH <1000 <1000 immunized with 5-KLH <1000 <1000 immunized with 6-KLH <1000 <1000 immunized with 7-KLH <1000 <1000 immunized with 8-KLH 7734 <1000 immunized with 9-KLH <1000 <1000 immunized with 10-KLH 7933 <1000 immunized with 11-KLH <1000 <1000 immunized with 12-KLH <1000 <1000 immunized with 13-KLH <1000 <1000 immunized with 14-KLH <1000 <1000 immunized with 16-KLH <1000 <1000 immunized with 17-KLH <1000 <1000 immunized with 18-KLH 1381 <1000 immunized with 19-KLH <1000 <1000 immunized with 20-KLH 11000 <1000 immunized with 21-KLH 1266 <1000 immunized with 22-KLH <1000 <1000 immunized with 23-KLH <1000 <1000 immunized with 24-KLH 6618 <1000 immunized with 29-KLH <1000 <1000 immunized with 30-KLH <1000 <1000 immunized with 31-KLH 20000 <1000 immunized with 32-KLH <1000 <1000 immunized with 33-KLH <1000 <1000 immunized with 34-KLH <1000 <1000 immunized with 42-KLH <1000 <1000

-   2)

TABLE 2 ELISA titers anti-STn 13 days after the third vaccination Group IgG IgM immunized with STn-KLH 50,144 5763 immunized with 3-KLH <2500 <1000 immunized with 4-KLH 17,040 1604 immunized with 5-KLH 38,878 1872 immunized with 6-KLH <2500 <1000 immunized with 7-KLH 23,279 4706 immunized with 8-KLH 43,201 4963 immunized with 9-KLH 4714 2897 immunized with 10-KLH 55,004 <1000 immunized with 11-KLH 4054 <1000 immunized with 12-KLH 11,783 <1000 immunized with 13-KLH 24,512 <1000 immunized with 14-KLH <2500 <1000 immunized with 16-KLH <2500 2571 immunized with 17-KLH 11,329 2047 immunized with 18-KLH 56,276 1842 immunized with 19-KLH <2500 <1000 immunized with 20-KLH 185,354 2581 immunized with 21-KLH 150,504 9236 immunized with 22-KLH 24,154 1586 immunized with 23-KLH 38,173 2880 immunized with 24-KLH 93,488 <1000 immunized with 29-KLH <2500 1979 immunized with 30-KLH <2500 <1000 immunized with 31-KLH 276,162 1804 immunized with 32-KLH <2500 <1000 immunized with 33-KLH <2500 <1000 immunized with 34-KLH 6108 <1000 immunized with 42-KLH <2500 <1000

-   3)

TABLE 3 IgG antibody titer anti-STn of individual mouse immunized with 20-KLH, 21-KLH, 31-KLH and 2-KLH after the 3rd vaccination STn-KLH 20-KLH 31-KLH 21-KLH Mouse 1 5,170 296,647 179,666 24,235 Mouse 2 6,385 79,799 356,282 182,259 Mouse 3 65,524 283,403 291,807 71,044 Mouse 4 96,812 63,561 83,396 85,645 Mouse 5 6,187 69,508 104,519 89,172 Mouse 6 18,663 68,401 351,977 472,834

-   4) The combination between the mice sera and the tumor cells 13 days     after the 3^(rd) vaccination -   The result is shown in FIG. 5. -   5) Result analysis -   The data of titers were dealt with logarithmic function to base 10     and after transformation the data satisfied conditions of ANOVA. The     F test is significant (F=5.18, p=0.0082). Dunnett's t Tests was used     in multiple comparisons. The results indicated that the IgG levels     for the conjugates of compounds 20, 21 and 31 exhibited a remarkable     increase relative to 2 after the 4th immunizations and the     difference was statistically significant (α=0.05). The statistical     analysis was performed with SAS software (version 9.1).

In vivo test of the effect of the synthetic glycoconjugates on killing tumor cells was not conducted. However, it is reported that (See British J. Cancer 2009, 100, 1746-1754) the anti-STn antibody (obtained after immunizing the mice) indeed represses tumor growth. Since higher titers of antibody were obtained in the present invention, it is expected that the repressive activity of the synthetic glycoconjugates surpasses that of the unmodified STn-KLH. 

The invention claimed is:
 1. A sialic acid (α-(2→6))-D-aminopyranose derivative or salt of the following Formula (1):

wherein R₁ is independently selected from the group consisting of —NHC(O)CH_(x)Cl_(y), —NHC(O)CH_(x)F_(y), —NHC(O)CH_(x)Br_(y), —NHC(O)H, —NHC(O)C_(a)H_(2a+1), —NHC(O)C_(a)H_(2a)OH, —NHC(O)C_(b)H_(2b−1), and —NHC(O)C_(b)H_(2b−3), —NH₂, —N₃, and —OH, where x and y is 0, 1, 2, or 3, and the sum of x and y is 3; a is an integer between 1 and 20; and b is an integer between 2 and 20; R₂ is independently selected from the group consisting of NHC(O)CH_(p)Cl_(q), —NHC(O)CH_(p)F_(q), —NHC(O)CH_(p)Br_(q), —NHC(O)H, —NHC(O)C_(a)H_(2a+1), —NHC(O)C_(a)H_(2a)OH, —NHC(O)C_(b)H_(2b−1), —NHC(O)C_(b)H_(2b−3), acylamino, —NH₂, —N₃, and —OH, where p and q is 0, 1, 2 or 3, and the sum of p and q is 3; a is an integer between 1 and 20; and b is an integer between 2 and 20; R₁ and R₂ are not —NHC(O)CH₃ simultaneously; R₃ is independently selected from the group consisting of —CO₂H, —CH₂OH, —CO₂M, C(O)NHOH and hydrogen, where M is alkyl, aryl or heteroaryl, and the orientation of the R₃ is an equatorial bond or an axial bond; R₄ is allyloxy; R₅ is —OH, and the orientation of the R₅ is an equatorial bond or an axial bond; and R₆ is Hydrogen or β-galactosyl-.
 2. A glycoconjugate characterized by conjugating the sialic acid-α-(2→6)-D-aminopyranose derivative or salt of claim 1 to a protein or a polypeptide.
 3. The sialic acid (α-(2→6))-D-aminopyranose derivative or salt claim 1, wherein the sialic acid (α-(2→6))-D-aminopyranose derivative or salt is characterized in that the salt is formed with a base.
 4. A process of preparing the sialic acid (α-(2→6))-D-aminopyranose derivative or salt of the following Formula (1), the process comprising: an acylation reaction in a solvent with carboxylic acid anhydrides, carboxylic acids or carboxylic esters in the presence of a reaction promoter, and using a sialic acid with 5-naked amino- and/or aminogalactose (aminoglucose) with 2-naked amino- as raw materials;

wherein R₁ is independently selected from the group consisting of —NHC(O)CH_(x)Cl_(y), —NHC(O)CH_(x)F_(y), —NHC(O)CH_(x)Br_(y), —NHC(O)H, —NHC(O)C_(a)H_(2a+1), —NHC(O)C_(a)H_(2a)OH, —NHC(O)C_(b)H_(2b−1), and —NHC(O)C_(b)H_(2b−3), —NH₂, —N₃, and —OH; where x and y is 0, 1, 2 or 3, and the sum of x and y is 3; a is an integer between 1 and 20; and b is an integer between 2 and 20; R₂ is independently selected from the group consisting of —NHC(O)CH_(p)Cl_(q), —NHC(O)CH_(p)F_(q), —NHC(O)CH_(p)Br_(q), —NHC(O)H , —NHC(O)C_(a)H_(2a+1), —NHC(O)C_(a)H_(2a)OH , —NHC(O)C_(b)H_(2b−1), —NHC(O)C_(b)H_(2b−3), —NH₂, —N₃, and —OH; where p and q is -0, 1, 2 or 3, and the sum of p and q is 3; a is an integer between 1 and 20; and b is an integer between 2 and 20; R₁and R₂ are not —NHC(O)CH₃ simultaneously; R₃ is independently selected from the group consisting of —CO₂H, —CH₂OH, —CO₂M, C(O)NHOH and hydrogen, where M is alkyl, aryl or heteroaryl, and the orientation of the R₃ is an equatorial bond or an axial bond; R₄ is allyloxy; R₅ is —OH, and the orientation of the R₅ is an equatorial bond or an axial bond; and R₆ is Hydrogen or β-galactosyl-.
 5. The Process of claim 4, wherein the preparation process is characterized in that the raw materials include allyl 4-O-(5-amino-3,5-dideoxy-α-neuraminopyranosyl)-2-acetylamino-2-deoxy-α-D-galactopyranoside, allyl 4-O-(5-acetylamino-3,5-dideoxy-α-neuraminopyranosyl)-2-amino-2-deoxy-α-D-galactopyranoside or allyl 4-O-(5-amino-3,5-dideoxy-α-neuraminopyranosyl)-2-amino-2-deoxy-α-D-galactopyranoside; the carboxylic acid anhydrides include aliphatic carboxylic acid anhydrides, with/without fluoro, chloro or bromo substituents; that the carboxylic acids include aliphatic acids, with/without fluoro, chloro or bromo substituents; that the carboxylic esters include aliphatic esters, with/without fluoro, chloro or bromo substituents; the promoter include organic or inorganic bases; and that the solvents include water or organic solvents.
 6. The Process of claim 5, wherein the preparation process is characterized in that the carboxylic acid anhydrides include acetic anhydride, propionic anhydride, n-butyric anhydride, iso-butyric anhydride and caproic anhydride; the carboxylic acids include mono-, di- and trifluoroacetic acid and mono-, dichloroacetic acid; and that the esters include methyl mono-, di- and trifluoroacetate and methyl dichloroacetate.
 7. A process of preparing a glycoconjugate, including (1) ozonization of the sialic acid (α-(2→6))-D-aminopyranose derivative or salt of claim 1 to give the corresponding disaccharide with aldehyde ; and (2) reductamination of the production obtained in step (1) with the carrier protein or polypeptide to give the conjugate.
 8. A method of producing an anti-tumor drug, the method comprising preparing the sialic acid (α-(2→6))-D-aminopyranose derivative or salt of claim 1 to produce the anti-tumor drug.
 9. A method of producing an anti-tumor drug, the method comprising preparing the glycoconjugate of claim 2 to produce the anti-tumor drug.
 10. A method of treating a tumor, comprising: administering to a subject in need thereof a composition comprising an effective dose the glycoconjugate of claim 2 and a pharmaceutically acceptable carrier or adjuvant. 